



FOSUN PHARMA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint st

Our Vision

We are committed to becoming a first-class enterprise in the global medical and healthcare market.


Our Mission

Better health for families worldwide.

Contents

| | |
|----|--------------------------|
| 02 | C a I m |
| 04 | F a a H |
| 05 | Ma a m D a A a |
| 48 | Ša D |
| 56 | I mC C a Ša m L |
| 57 | I mC C a Ša m C m I m |
| 58 | I mC C a Ša m F a a |
| 60 | I mC C a Ša m C a E |
| 62 | I mC C a Ša m C a F |
| 64 | N I mC C a F a a I m |
| 99 | D |

Corporate



Directors

Executive Directors

M. 吳以芳 (吳以芳) (Chairman)
M. 王可心 K (王可心) (Co-Chairman)¹
M. 關曉暉 G (關曉暉) (Vice-Chairman)²
M. 文德鏞 D (文德鏞) (Chief Executive Officer)³

Non-executive Directors

M. 陳啟宇 C (陳啟宇)
M. 姚方 F (姚方)
M. 徐曉亮 X (徐曉亮)
M. 潘東輝 D (潘東輝)

Independent Non-executive Directors

M. 李玲 L (李玲)
M. 湯谷良 G (湯谷良)
M. 王全弟 Q (王全弟)
M. 余梓山 S (余梓山)

Supervisors

M. 任倩 Q (任倩) (Chairman)
M. 曹根興 G (曹根興)
M. 管一民 G (管一民)

Joint Company Secretaries

M. 董曉嫻 D (董曉嫻)
M. 甘美霞 M (甘美霞)

Authorized Representatives

M. 吳以芳 Q (吳以芳)
M. 甘美霞 M (甘美霞)

Strategic Committee

M. 吳以芳 Q (吳以芳) (Chairman)⁴
M. 陳啟宇 C (陳啟宇)⁵
M. 姚方 F (姚方)
M. 徐曉亮 X (徐曉亮)
M. 李玲 L (李玲)

Audit Committee

M. 湯谷良 G (湯谷良) (Chairman)
M. 王全弟 Q (王全弟)
M. 李玲 L (李玲)

Nomination Committee

M. 王全弟 Q (王全弟) (Chairman)
M. 李玲 L (李玲)
M. 潘東輝 D (潘東輝)

Remuneration and Appraisal Committee

M. 余梓山 S (余梓山) (Chairman)
M. 湯谷良 G (湯谷良)
M. 王全弟 Q (王全弟)
M. 陳啟宇 C (陳啟宇)
M. 潘東輝 D (潘東輝)

Environmental, Social and Governance Committee

M. 余梓山 S (余梓山) (Chairman)
M. 李玲 L (李玲)
M. 吳以芳 Q (吳以芳)

Registered Office

9 F, N. 510 C, D
S, 200063, C

Principal Place of Business in the PRC

B A
N. 1289 C
S, 200233, C

¹ 吳以芳 於 2022 年 4 月 1 日獲委任為本公司之共同主席。
² 關曉暉 於 2022 年 1 月 1 日獲委任為本公司之副主席。
³ 文德鏞 於 2022 年 1 月 1 日獲委任為本公司之首席執行官。
⁴ 吳以芳 於 2022 年 1 月 1 日獲委任為本公司之主席。
⁵ 陳啟宇 於 2022 年 1 月 1 日獲委任為本公司之副主席。

⁴ 吳以芳 於 2022 年 1 月 1 日獲委任為本公司之主席。
⁵ 陳啟宇 於 2022 年 1 月 1 日獲委任為本公司之副主席。

Principal Place of Business in Hong Kong

5/F, Manulife Building
348 Kowloon Road East, Kowloon
Hong Kong

Legal Advisers in Hong Kong

Shum & Bak LLP

Legal Advisers in the PRC

Guangdong Law Firm (Shanghai)

Auditors

EY &
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, Bank of China Tower
979 Kowloon Road East, Kowloon
Hong Kong

Principal Banks

Industrial and Commercial Bank of China
Citibank
Industrial and Commercial Bank of China
Bank of China
Citibank
Industrial and Commercial Bank of China

Corporate Name

Shanghai F&B Investment (Group) Co., Ltd.*

Stock Abbreviation

F&B N HA MA

Share Listing

Listing: Shanghai Stock Exchange
Stock Code: 600196
Listing: Shenzhen Stock Exchange
Stock Code: 02196

A Share Registrar and Transfer Office in the PRC

China Depository and Clearing Co., Ltd.
(CSDCC) Shanghai Branch
188 Zhongyuan Road
District
Shanghai, China

H Share Registrar and Transfer Office in Hong Kong

International
17/F, Finance House
16 Harbour Road
Hong Kong

Corporate Website

://www.f&b.com.hk

* Shanghai F&B Investment (Group) Co., Ltd. is a company registered in the PRC under the laws of the PRC.

Financial H

For the six months ended 30 June

| | 2022 RMB million | 2021 MB 卄 (卄) |
|---|---|---------------------------------|
| Operating results | | |
| | 21,275 | 16,878 |
| G | 9,699 | 8,621 |
| 卄 | 1,999 | 1,343 |
| 卄 | 2,379 | 3,304 |
| 卄 | 1,554 | 2,482 |
| EBI DA | 3,881 | 4,670 |
| Profitability | | |
| G 卄 | 45.59% | 51.08% |
| 卄 卄 | 9.40% | 7.96% |
| N 卄 | 8.79% | 16.32% |
| Earnings per share (MB 卄) | | |
| E卄 卄 卄 | 0.60 | 0.97 |
| E卄 卄 | 0.60 | 0.97 |
| Of which: Pharmaceutical manufacturing segment | | |
| | 14,271 | 12,179 |
| G | 7,762 | 6,965 |
| 卄 卄 | 1,890 | 1,353 |
| 卄 卄 | 1,579 | 1,257 |
| | 30 June 2022 RMB million | 31 D 卄 2021 MB 卄 |
| Assets | | |
| 卄 卄 | 98,754 | 93,237 |
| E 卄 卄 | 38,148 | 39,135 |
| 卄 卄 | 51,070 | 44,918 |
| C卄 卄 卄 卄 | 12,258 | 10,308 |
| D - 卄 卄 | 51.71% | 48.18% |

FINANCIAL REVIEW

D
 2021, 26.05%
 G
 MB21,275
 2021, 26.05%
 MB1,999
 MB1,820
 BN
 G
 2021, BN MB1
 D
 MB-260
 MB1,567
 MB1,307
 D
 MB1,554
 38.14% MB0.60
 G
 &D. D
 22.77%
 MB256 16.39%
 &D
 MB2,399
 MB1,818

REVENUE

D
 26.05%
 G
 MB7,592
 35.69%
 G
 MB21,275
 MB13,683
 G

Management

D A A

GROSS PROFIT

D 2021. G 12.50% MB9,699 MB8,621
 ; (1)
 ; (2)
 ; (3)
 G
 45.59%,
 5.49
 C
 G

SELLING AND DISTRIBUTION EXPENSES

D MB4,166 MB4,211 G MB45 1.07%
 19.58%, 5.37
 ; (1)
 ; (2)
 ; (3)
 H
 C
 G

R&D EXPENSES AND R&D EXPENDITURE

D MB2,399 G &D MB1,818
 22.77%. I &D
 MB256 16.39%. D
 MB2,062
 MB285 16.04%, 14.39%
 &D MB1,491 MB106 7.65%
 10.41%
 &D

OTHER GAINS AND OTHER EXPENSES

D MB1,645 G MB994 60.43% MB651
 BN
 D MB338 G MB573 169.53% MB911
 BN

SHARE OF PROFITS OF ASSOCIATES

D , A A A G A 2.92% MB899 m m
 MB926 m 2021.

PROFIT FOR THE PERIOD

D A A , G A 32.14%
 MB1,869 m m MB2,754 m 2021. m
 G A 2021 8.79% A 16.32%, .

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

D , G A A m MB1,999 m , A - -
 A MB656 m . A m A A A A BN
 G A A m A 2021, A m A A A
 A A A A BN A MB1 . D , A A
 m A A A A A , G A - - A MB1,567 m
 A A . D A A , G A A A
 A A m MB1,554 m , A - - A 37.39%.

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

A A 30 J 2022, A G A MB30,461 m m MB25,299 m A A 31 D m 2021
 m . A A 30 J 2022, m - - - m G A
 41.76% A , A A 3.43 A A m A 38.33% A A 31 D m
 2021. D m - - - m A m A A m
 - A A . A A 30 J 2022, A A A A A 18.92% MB12,258 m m
 MB10,308 m A A 31 D m 2021.

A A 30 J 2022, A A m MB8,698 m (31 D m 2021: MB7,382 m) A
 G A m A , A m A A m MB.

A A 30 J 2022, A A A A A G m A A m MB4,928 m (31
 D m 2021: MB4,276 m).

Management

D A A

| | : m | C | : MB |
|--|-----------------|------|-----------|
| | 30 June 2022 | 31 D | m 2021 |
| Cash and cash equivalents denominated in: | | | |
| MB | 7,330 | | 6,032 |
| US\$ | 1,721 | | 1,615 |
| | 2,220 | | 1,907 |
| HK\$ | 577 | | 560 |
| E | 156 | | 78 |
| | 254 | | 116 |
| | 12,258 | | 10,308 |

Gearing Ratio

As at 30 June 2022, the Group's gearing ratio (defined as the ratio of total debt to total capitalization) was 30.85%, compared to 27.13% as at 31 December 2021.

Interest Rate

As at 30 June 2022, the Group's interest rate was 4.5% (31 December 2021: MB7,968 million).

Maturity Structure of Outstanding Debts

| | : m | C | : MB |
|-----------|-----------------|------|-----------|
| | 30 June 2022 | 31 D | m 2021 |
| 1 year | 17,740 | | 15,602 |
| 1-2 years | 4,648 | | 5,067 |
| 2-5 years | 5,753 | | 2,073 |
| 5 years | 2,320 | | 2,557 |
| | 30,461 | | 25,299 |

Available Facilities

A ଚ 30 J 2022, ଚ ଚ ଚ ଚ ଚ MB12,258 ଟଙ୍କା , G ଚ ଚ ଚ ଚ ଚ
 MB31,327 ଟଙ୍କା ଚ ଚ ଚ G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ .A
 ଚ ଚ ଚ ଚ ଚ ଚ ଚ G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ
 ଚ .A
 ଚ 30 J 2022, ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB57,845 ଟଙ୍କା
 ଚ ଚ ଚ , MB26,518 ଟଙ୍କା ଚ ଚ ଚ .

I A 2020, C ଟଙ୍କା ଚ ଚ ଚ ଚ ଚ ଚ ଚ C.S.C ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ
 ଟଙ୍କା ଚ MB5,000 ଟଙ୍କା ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ 31 D ଟଙ୍କା 2022. I
 J 2022 ଚ A 2022, C ଟଙ୍କା ଚ ଚ ଚ ଚ ଚ ଚ NAFMII ଚ ଚ ଚ ଚ ଚ
 - ଟଙ୍କା ଟଙ୍କା ଚ ଚ ଚ MB6,000 ଟଙ୍କା ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB4,000 ଟଙ୍କା C ଟଙ୍କା ଚ ,
 ଟଙ୍କା ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ .

Collateral and Pledged Assets

A ଚ 30 J 2022, G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ : ଚ ଚ ଚ ଚ ଚ ଟଙ୍କା
 ଚ ଟଙ୍କା MB772 ଟଙ୍କା (31 D ଟଙ୍କା 2021: MB550 ଟଙ୍କା) ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB511
 ଟଙ୍କା (31 D ଟଙ୍କା 2021: MB514 ଟଙ୍କା) .

A ଚ 30 J 2022, G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ : ଚ ଚ ଚ ଚ ଚ ଚ ଟଙ୍କା
 MB100 ଟଙ୍କା (31 D ଟଙ୍କା 2021: MB69 ଟଙ୍କା) ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB8 ଟଙ୍କା (31 D ଟଙ୍କା 2021:
 MB8 ଟଙ୍କା) .

A ଚ 30 J 2022, ଟଙ୍କା ଚ (31 D ଟଙ୍କା 2021: MB8 ଟଙ୍କା)
 ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ .

A ଚ 30 J 2022, G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ : 58.67% ଚ ଚ ଚ ଚ ଚ ଚ
 A ଚ ଚ (31 D ଟଙ୍କା 2021: 58.67% ଚ ଚ ଚ A ଚ ଚ) .

D ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ 16 ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ .

Cash Flow

ଚ ଚ G ଟଙ୍କା ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ , ଚ ଚ ଚ ଚ ଚ ଚ ଚ , ଚ
 ଚ ଚ ଚ ଚ ଚ ଚ , ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ G ଚ ଚ ଚ
 ଚ ଚ G ଚ ଚ ଚ ଚ () ଚ ଚ ଚ , ଚ ଚ ଚ ଚ ଚ ଚ ଚ
 ଚ 2021.

A ... (N.SCLC)), ... (E.S.SCLC)) ...
 (... (E.SCC)) HA ... C MA ...
 ... HA ... (SCLC) ... D
 D ... FDA. D , F.S-1502 ...
 (N.SCLC) ... II ... C MA ... F.S-1502 ... / ...
 ... HE 2- ... C MA ...
 ... II ... FCN-159 ...
 ... II ... C MA ... F K '
 CA - ... , FK889 (...) ...
 ... (/ MCL) ...) ... C
 MA ... C ... (NA C ID-19 ...) ...
 ... 5 11 MA ... , C ... A ... MA 2022 ...
 ... 6 ... 4 ... A 2022 ... , C ... I A 2022, G ' -
 C ID-19 ... C MA ... I ... , J 2022,
 ... F ... I ... G B ...
 ... , ... F ... I ...
 ... A ... C ID-19 ...
 AID ... A ... C ...
 C ID-19 ...

D ... , 2 ... (...) ... 10 ... (...) G ...
 ... C MA ... / ... 1 ... (...) ... 18
 (...) ... (NDA) C MA ... 14 ... (...) ... 9
 (...) ... (IND) C MA ...

F ... &D ... G ' ... (...)
 ... 1 ... 3.

Table 1 — Innovative drugs approved for launch during the Reporting Period

| No. | Name of drugs | Classification of registration | Indications | Remarks |
|-----|--------------------|--------------------------------|-------------------|---------|
| 1 | HA ... (...) | ... | M ... (M.S-H) ... | A ... |
| 2 | HA L K ... (...) | ... | ... A (A) | / |

Table 2 — Innovative drugs applied for launch during the Reporting Period

| No. | Name of drugs | Classification of registration | Indications |
|-----|----------------|--------------------------------|--|
| 1 | HA ... (...) | ... | I ... (...) - (E.S.SCLC) |

Table 3 — Innovative drugs that obtained clinical approvals during the Reporting Period

| No. | Name of drugs | Classification of registration | Indications |
|-----|------------------------------------|--------------------------------|-------------------|
| 1 | FCN-159 | C | H |
| 2 | FCN-159 | C | A |
| 3 | IN1001 | C | I (I F) |
| 4 | HL 208 | C | ≤ |
| 5 | | C | E (D) (MD - B) |
| 6 | F-1502 (-HE 2 - F) / | | HE 2- |
| 7 | FKC889 ^{Note} | | M (/ MCL) |
| 8 | HL 35 (-EGF -4-1BB) | | ≤ |
| 9 | HL 53 (- IGI F) | | ≤ |
| 10 | HL 301 (- D-L1 - IGI) | | A |
| 11 | H () | | I (L-SCLC) |
| 12 | H ()+HL 07 (-EGF)+H B () | | H (HCC) |
| 13 | HL 26 (-LAG-3)+H () | | ≤ |
| 14 | ≤ N53-67/M57-KLH (≤ M) | | |

Note: F K ,

ମାମା G ମାମା ବ ବ ବ
ବ :

: ମ C : MB

| Major therapeutic area | Jan – Jun 2022 | Jan – Jun 2021* | ବ ବ ବ (%) |
|---|----------------|-----------------|--------------|
| ମାମା ବ - ମାମା ମାମା ମାମା (Notes 1, 7) | 2,550 | 1,705 | 49.56 |
| ମାମା ବ - (Notes 2, 7) | 3,629 | 2,656 | 36.63 |
| ମାମା ମାମା ମାମା ବ ମାମା ମାମା (Notes 3, 7) | 1,383 | 1,419 | 2.54 |
| ମାମା ବ ବ ବ ମାମା (Notes 4, 7) | 1,095 | 1,019 | 7.46 |
| ମାମା ବ ମାମା (Notes 5, 7) | 422 | 616 | 31.49 |
| ମାମା A I ବ ମାମା (Notes 6, 7) | 633 | 577 | 9.71 |

Note 1: ମାମା ବ - ମାମା ମାମା ମାମା ବ - - - - - 49.56%, ମାମା
H (ବ ମାମା), H L K (ମାମା) ବ ଓ K (ବ ମାମା ବ ମାମା ବ ବ), ବ
ମାମା H ଓ ବ (ମାମା) ବ A (N ବ ବ ବ H
Cା) .

Note 2: ମାମା ବ - - - - - 36.63%, ମାମା
C ମାମା (ମାମା NA C ID-19 ବ) ବ ବ ମାମା ବ ବ ବ ବ .

Note 3: ମାମା ମାମା ମାମା ବ ମାମା ମାମା ମାମା - - - - - 2.54%, ମାମା
ବ ମାମା A ମାମା (ବ) ବ F K J (ବ) ବ
ବ ମାମା .

Note 4: ମାମା ବ ବ ବ ମାମା ବ - - - - - 7.46%, ବ ମାମା
ବ ବ ବ .

Note 5: ମାମା ବ ମାମା ବ - - - - - 31.49%, ମାମା
ମାମା A D J (ବ ମାମା) .

Note 6: ମାମା A I ବ ମାମା ବ - - - - - 9.71%, ମାମା
ବ ମାମା .

Note 7: ମାମା ବ - ମାମା ମାମା ମାମା ମାମା : H (ବ ମାମା), H L K (ମାମା), ଓ K
(ବ ମାମା ବ ମାମା ବ ବ), H ଓ ବ (ମାମା), K ଓ (ବ ବ), K L (ବ
ବ), ବ H ବ (ବ ବ), D K M (ବ ବ ବ), H D ବ (A ବ ମାମା), L / M ଓ (ମାମା
ମାମା), ବ ବ , ବ , ବ ବ ବ A (N ବ ବ ବ H
Cା) .

ମାମା ବ - ମାମା : C ମାମା (ମାମା NA C ID-19 ବ), ବ ମାମା ବ ବ ବ ବ , C ବ / B L ଓ
(ମାମା ମାମା), ବ ବ (E) ମାମା (-), M ଓ L (ମାମା ମାମା),
M ବ , ଓ ବ D L K (ବ ମାମା ମାମା ବ ବ ବ ବ), ବ , ବ ଓ L (ବ
ମାମା ବ ବ ବ ମାମା), ବ ମାମା , ବ ଓ L / ଓ / E (ବ ମାମା ବ ବ ମାମା
), ବ , H D (ବମାମା ବ), E B (ମାମା ମାମା), ବ ମାମା , K D (ବ ମାମା
), ଓ K N (ବ ମାମା ବ) ବ ଓ N (ବମାମା ବ) .

Management

D A A

Ma (), Ba (), L (), Ba L (H), , K J A (), (), ().

Ma (), K (), A (), D E (), N A (), K ().

Ma A D J (), C N (), C ().

Ma A I (), (), (), ().

* () J 2021 () J 2022, (), () J 2021 () L D A () H A ().

Important events

- Progress of PD-1 inhibitor Han Si Zhuang (serplulimab injection)

I Ma 2022, () (M.S-H) () D-1 H () G () NM A () M.S-H () A 26 A 2022, H () C 18 ().

A () NDA () (N.SCLC), () (E.S-SCLC) () () (E.SCC) H () C M () H () (SCLC) D D () FDA. I (), () (E.S-SCLC), III () (), () I D () M C (IDMC). () () 15.4 () 10.9 (), () 24- () 43.1% () 7.9%.

A () H () HL 07 () EGF () H B () (HCC) II C Ma () III H () (+5-F) () (E.SCC) () (F.S) () I D M C (IDMC).

Ba () C +G () H () () A () 11 () H () ().

Progress of CAR-T cell therapy products

Ka Da () F K a ... CA - ... K ... J 2021, ... CA - ... B- ... (/ DLBCL) ... A ... J 2022, Ka Da ... 44 ... 100.

Ka Da () -H ... NHL) ... C Ma ... 2021. A ... C Ma ...

Ka Da () B- ... (/ LBCL) ... 12 ... A 2022. I A ... FDA ... CA - ... FDA ... LBCL. ... MA-1 ... 5- ... () ... / ... LBCL ... 42.6%, ... 5- ... C ... 64.4%. ... Ka Da, ...

I a , F K ' CA - ... FK889 ... C ... Ma 2022 ... (/ MCL) a ... A ... C Ma ...

Cooperation on the joint development and exclusive commercialization of Azvudine

I J 2022, ... F ... G B ... A ... (2019- C) ... AID ... A ... C ... 25 J 2022, ... NM A ... C ID-19. ... NM A ... HI -1 ... (. . AID ...) ...

9 A 2022, A ... D ... G ... C ID-19 (9 E) (《新型冠状病毒肺炎诊疗方案(第九版)》). A ... A ... G ... H ... J ... H ... G ... F ... C ... A ... A ... HI ... H ... C ID-19 ...

Management

D A

- Other license-in and license-out projects

&D ... 20 ... G ... K ... B N ... App ...

L ... G ... C ... G ... App ...

(...), C ... Ma ... NM A A 2021, ... -4 (DE4) ...

App ... G ...

WT ... G ... D ... H ... I F ... 2022, ... H ... G ...

... HL 11 (... -HE 2 ... II ...) ... D ... HL 14 (... - ANKL ...) ... C ... \$538 ... \$70 ...

E ...

• Deepening of global operation

... G ... A ... G ... A ... 6,099 ... 16.7% ... G ...

I ... G ... 22 ... 2019- C ... 5 ... 16 ... (G) ... 21 ... 85% ... (IDN) ...

I ... A ... G ... 5 ... 800 ... B2B2C ... - ... G ... A ... K ... I ... C (IC C) ... A ... H - ... I J 2022, ... III ... A ...

G ... 2022, ... F ... M ... C ID-19 ... M ... N ... C ID-19 ... N ... M ...

R&D innovation

L ... &D ... G ... &D, ... (BD) ... &D ... A ... G ... &D, ... NA, ... ADC ... &D ...

A ... 260 ... G ... 4). ... D ... 51 ... 26 ... G ... 6 ... 6 C ... 26 ...

Table 4 — Major pipeline drug projects

| Type | Number (calculated according to indications) | Remarks |
|--|--|----------------------|
| Innovative drugs | 70 | / |
| I : Sma m a | 22 | F a m a a 5. C m 3 |
| B a m a a | 32 | F a m a a 6. C m 2 |
| L - a | 16 | F a , a a 7. C m 1 m |
| Biosimilars under independent development | 13 | F a , a a 8. C m 2 m |
| Generic drugs | 130 | / |
| I : m | 14 | / |
| Consistency evaluation items | 23 | / |

Note 1: a

G a a m a.

Note 2: a

CD19- a a CA - a FK889 F K , a , a m a a m a (/ MCL) a - m a , a a a a C M a a . A a , a a a a a a

Table 5 — Small molecular innovative drugs under independent development

| No. | Therapeutic area | Drug name/code | Indications | R&D progress in Chinese Mainland as at the end of the Reporting Period | R&D progress in other countries as at the end of the Reporting Period |
|-----|------------------|----------------|------------------|--|---|
| 1 | A - m | FCN-338 | H m a m a | a a a | a a a (.s) |
| 2 | | | a a B- m m | A a a | |
| 3 | | FCN-159 | M a m a m | a a a | |
| 4 | | | N m | a II a a (a a m -) | |
| 5 | | | L - a m | A a a | |
| 6 | | | H m | a II a a | |
| 7 | | IN1001 | s m | a a a | a a a (.s) |
| 8 | | SAF-189 | N - m a a (s1+) | a II a a | A a a (.s) |
| 9 | | | N - m a a (ALK+) | a III a a | |
| 10 | | FCN-437 | B a a 1L | a III a a | a a a (.s) |
| 11 | | | B a a 2L | a III a a | |
| 12 | | 01001 | A a m | a a a | |
| 13 | | FH-2001 | A a m a m | a a a | |
| 14 | M a m a m a m | FCN-342 | G | a a a | |
| 15 | | IN1001 | I a m a (I F) | A a a | a a a (.s) |
| 16 | | E -26 | A a | a II a a | |
| 17 | | FCN-159 | A m m | A a a | |

Table 6 — Biopharmaceutical innovative drugs under independent development

| No. | Therapeutic area | Drug name/code | Indications | R&D progress in Chinese Mainland as at the end of the Reporting Period | R&D progress in other countries as at the end of the Reporting Period | |
|-----|------------------|---|--------------------------------|--|---|-----------------------|
| 1 | A - m | Hx S a (ma) | M a a - (M.S-H) m | A a | A a a (note 1) | |
| 2 | | Hx S a (ma)+ m a | S am - ma a (NSCLC) | a a a | a III a a (a a m -) | |
| 3 | | | E - a ma a (E.S.SCLC) | a a a | a III a a (a a m -) | |
| 4 | | | E a a am a ma (ESCC) | a III a a (note 2) | | |
| 5 | | | N -/a a am GC | a III a a | | |
| 6 | | | Lm - a ma a (L.S.SCLC) | a III a a (a a m -) | | |
| 7 | | Hx S a (ma)+ Ha B a (a ma) | N - am - ma a (NSCLC) | a III a a | | |
| 8 | | | H a a a ma (HCC) | a II a a | | |
| 9 | | | M a a a a (mC C) | a III a a | | |
| 10 | | Hx S a (ma)+HL 07 (m a a -EGF ma) | m a a a a a am a ma (HN.SCC) | a II a a | | |
| 11 | | | S am - ma a (NSCLC) | a II a a | | |
| 12 | | Hx S a (ma)+HL 07 (m a a -EGF ma)+Ha B a (a ma) | H a a a a ma (HCC) | A a a | | |
| 13 | | HL 26(m a a -LAG-3 ma m a a)+Hx S a (ma) | S m a m ma | A a a | | |
| 14 | | HL 22(a - ma ma a -2 (HE 2) ma m a a)+Ha (a ma) | Gr a (GC) | a II a a | | |
| 15 | | HL 07(m a a -EGF ma m a a) | S m (-ma a , a a a a) | a I/II a a (note 3) | A (.S) | |
| 16 | | HL 20(m a a -D-L1 ma m a a) | S m | A a a | a I a a (A a a) | |
| 17 | | HL 26(m a a -LAG-3 ma m a a) | S m a m ma | a I a a | | |
| 18 | | HL 35(m a ma a -EGF a a 4-1BB a) | S m | a I a a | a I a a (A a a) | |
| 19 | | HL 301(m a a -D-L1 a a - IGI a) | S m | A a a | a I a a (A a a) | |
| 20 | | HL 23(m a a -CD73 ma m a a) | S m | | A a a (.S) | |
| 21 | | HL 53(a - IGI F) | S m a m ma | A a a | | |
| 22 | | HL 60(m a ma a -GA m a a)+Hx S a (ma) | A a /m a a m | | (Note 4) | |
| 23 | | B m | m a H ma E -H F F I | A ma | a I/II a a | |
| 24 | | | HL 04- (m a a -EGF ma m a a) | m a - a ma a a (AMD) | a III a a | a III a a (a a m -) |

Note 1: Hx S a (ma) IND a a S a , E a .

Note 2: I Ma 2022, a III a Hx S a (ma) m a m a a . I A 2022, NDA C Ma a a a a m a a a a ma m ma . I A NM A.

Note 3: Am a I/II a a C Ma a , a a a a a , C a a m .

Note 4: I A 2022, HL 60 (m a ma a -GA m a a) m a Hx S a (ma) a m a a /m a a m a a a I a a A a a.

Table 7 — License-in innovative drugs

| No. | Therapeutic area | Drug name/code | Indications | R&D progress in China as at the end of the Reporting Period |
|-----|-----------------------|---|--|---|
| 1 | A - m | ≤ N53-67/M57-KLH a (≤ a M) | m a a m a | A a a |
| 2 | | HL 208 | ≤ m (m a a a a a , - m a a ,) , LCH a ECD | a II a a |
| 3 | | F≤1502 (m a a - HE 2 m a m a a - m m a a F a) | N - m a a (N≤CLC) | a II a a |
| 4 | | | HE 2- a a a m a a a a | a I a a |
| 5 | | | HE 2 a a m a a m | a II a a |
| 6 | | F≤1502 (m a a - HE 2 m a m a a - m m a a F a) m a m a a / m a | HE 2- a a a a | A a a |
| 7 | M a m a a m a m | a a a | I a m a (IB≤C) | a I a a |
| 8 | | F a a | I a a | a III a a |
| 9 | A - | m NA a BN 162 2 | a (C ID-19) a a (SA ≤C -2) | C M a a : a II a a m H K , C a : A m M a a , C a : a a a m a a m a a a , C a : a a a a m |
| 10 | | m a a | E - a (D) m - a (MD - B) a m a / a a m | a I a a |
| 11 | C a m | a a | a m | NDA |
| 12 | B m | A a m a m a a a | C m m m a (I) | a III a a |
| 13 | | a a a | H a m a - a a a a a (E≤ D-HD) | a III a a |
| 14 | | F a a (a a a) | m a a a | a III a a |
| 15 | | 002 (Da m A) | M a a a a a (GL) | a III a a |
| 16 | | | I a a a (CD) | a III a a |

Table 8 — Biosimilars under independent development

| No. | Therapeutic area | Drug name/code | Indications | R&D progress in Chinese Mainland as at the end of the Reporting Period |
|-----|-----------------------|--|--|--|
| 1 | A - m | HL 11 (m a a -HE 2 m a m m a a) | N a a a m BC | a III a a |
| 2 | | HL 05 (m a A -EGF H m a /M C m M a A) | M a a a a (mC C)a m a a a a a m a m a (HNSCC) | a I a a |
| 3 | | HL 12 (m a a - EGF 2 m a II-III m a m a a) | G a a (GC), m a a - m a a (NSCLC) a m a a a a (mC C) | a I a a |
| 4 | | HL 13 (m a a -C LA-4 m a m a a) | M a m a, a a m a (CC)a m a a a a (mC C) | A a a |
| 5 | | HL 15 (m a a -CD38 m a m a a) | M m m a (MM) | A a a |
| 6 | | H a B a (a m a) | a m a | (Note 1) |
| 7 | | | H a a a a m a | (Note 2) |
| 8 | M a m a a m a m | I a | D a | NDA |
| 9 | | m a | D a | A a |
| 10 | | M a m a m a (50) | D a | a III a a (Note 3) |
| 11 | | L a | D a | a III a a |
| 12 | | HL 14 (m a a - ANKL m a m a a) | () | a III a a (a a m -) |
| 13 | | H a L K a (m a) | m a A (A) | A a |

Note 1: m a a a a (NDA) H a B a (a m a) a a a m a a a
a NM A J 2022.

Note 2: NDA H a B a (a m a) a a a a a m a a a NM A A
2022.

Note 3: NDA m a m a m a (50) a a NM A J 2022.

A a , a a 25 G a a a m a a a
a a a a m a (a a , a a a 9 a a m a). F
a m a , G a a a a a m a - a m a a
m a a m a a m a a m a a m a a a
m m a m a m a a m a m a m a m a
m a a a a a m a .

Table 9 — Products won tenders for centralized procurement

I ಉಚಿತ ಶೇಖರಣೆ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ \$175
ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ \$20.53 ಉಚಿತ ಶೇಖರಣೆ (ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ
) , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ - - ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ
ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ
ಉಚಿತ ಶೇಖರಣೆ &D ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ .D
ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ - ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ
ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ .I
ಉಚಿತ ಶೇಖರಣೆ 2022, ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ &D, ಉಚಿತ ಶೇಖರಣೆ
ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ .I Ma 2022,
ಉಚಿತ ಶೇಖರಣೆ - ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ LMN , ಉಚಿತ ಶೇಖರಣೆ , LMN , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ
ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ C ಉಚಿತ ಶೇಖರಣೆ | ಉಚಿತ ಶೇಖರಣೆ .I ಉಚಿತ ಶೇಖರಣೆ , ಉಚಿತ ಶೇಖರಣೆ ಉಚಿತ ಶೇಖರಣೆ A ಉಚಿತ ಶೇಖರಣೆ ED ಉಚಿತ ಶೇಖರಣೆ CBD+

Management

D A

Healthcare services

D - - , 58.27%. E MB2,917 m , H
 38.42% H
 MB368 m . MB 442 m , MB 387 m
 MB427 m .
 C ID-19 , G , F H , G
 A G 8
 G
 G
 A 5,732
 C
 G
 Na Na F C
 F C H 14 F - F A H A
 M

Management

D A

Financing

I G
 D G 2022, C MB500
 I J 2022, C MB4,484 A 106,756,666 A
 G &D

2. Core Competitiveness Analysis

D G &D
 A. A &D G
 B. A &D, G BD &D
 C. A G 6,900 2,000 1,400

3. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1) Analysis of Changes in Relevant Items of Financial Statements

| Items | Amount for the period | Amount for the corresponding period of last year | Period-on-period change (%) |
|----------------|-----------------------|--|-----------------------------|
| (Note 1) | 21,275 | 16,878 | 26.05 |
| C (Notes 2, 7) | 11,576 | 8,256 | 40.21 |
| Σ (Note 3) | 4,166 | 4,211 | 1.07 |
| A &D | 1,715 | 1,505 | 13.95 |
| F | 1,818 | 1,562 | 16.39 |
| (Note 4) | 438 | 421 | 4.04 |
| (Note 5) | 651 | 1,645 | 60.43 |
| | 911 | 338 | 169.53 |
| N | 1,820 | 1,707 | 6.66 |
| N | 2,485 | 2,450 | 1.43 |
| N (Note 6) | 2,420 | 770 | 214.29 |

Note 1: F A , Σ M MB A D

Note 2: (1) (2) (3) 45.59%, 5.49%

Note 3: Σ MB45 19.58%, 5.37 (1) G

BN 48 262 4.859 -2.714 (48 9 M) * 1 3 1 0.038 /Σ A A 6FF000

Principal operations by products

| By products | Revenue | Cost of sales | Gross profit margin (%) | Period-on-period change in revenue (%) | Period-on-period change in cost of sales (%) | Period-on-period change in gross margin |
|-------------|---------|---------------|-------------------------|--|--|---|
| Ma (Note 4) | 2,550 | 493 | 80.67 | 49.56 | 27.06 | 3.43 |
| Ma (Note 5) | 3,629 | 1,701 | 53.13 | 36.63 | 43.67 | 2.29 |
| Ma | 1,383 | 289 | 79.10 | 2.54 | | 0.53 |
| Ma (Note 6) | 1,095 | 706 | 35.53 | 7.46 | 16.50 | 5.00 |
| Ma (Note 7) | 422 | 41 | 90.28 | 31.49 | 6.82 | 2.58 |
| Ma A I | 633 | 476 | 24.80 | 9.71 | 8.43 | 0.88 |

Principal operations by geographical locations

| By geographical locations | Revenue | Cost of sales | Gross profit margin (%) | Period-on-period change in revenue (%) | Period-on-period change in cost of sales (%) | Period-on-period change in gross margin |
|---------------------------|---------|---------------|-------------------------|--|--|---|
| C Ma (Note 8) | 13,683 | 6,860 | 49.86 | 17.15 | 27.08 | 3.92 |
| C Ma (Note 9) | 7,592 | 4,716 | 37.88 | 46.06 | 65.01 | 7.14 |

Note 1: (1) (2) B G C

Management

D A A

- Note 2: (1) ; (2) ; (3)
- Note 3:
- Note 4:
- Note 5:
- Note 6:
- Note 7:
- Note 8:
- Note 9:
- Note 10: F G
- Note 11: C 2021

Management

D A A

(2) Operation and Results of Investee Companies whose Net Profit and Investment Income Contributing More Than 10% of the Group's Net Profit

| Company name | Major business | Registered capital | Total assets | Net assets | Revenue | Operating profit | Net profit |
|--------------|----------------|--------------------|--------------|------------|---------|------------------|------------|
| 上海医药集团股份有限公司 | 医药商业 | 100 | 370,124 | 104,237 | 261,472 | 7,988 | 6,221 |

(3) Acquisition and Disposal of Subsidiaries for the Reporting Period (including the Purposes and Methods of the Acquisitions and Disposals and their Effects on the Group's Overall Operation and Results)

| Company name | Acquired through | Net assets (as at the end of Reporting Period) | Net profit (from date of merger/acquisition up to the end of Reporting Period) | Date of acquisition/merger |
|------------------|------------------|--|--|----------------------------|
| ① A 上海医药集团股份有限公司 | 收购 | | | 2022年6月 |

| Company name | Acquired through | Net assets (as at the end of Reporting Period) | Net profit (from date of merger/acquisition up to the end of Reporting Period) | Date of acquisition/merger |
|----------------|------------------|--|--|----------------------------|
| H 上海医药集团股份有限公司 | E 收购 | 646 | 8 | 2022年6月 |

Note: 上海医药集团股份有限公司收购上海医药集团股份有限公司子公司上海医药集团股份有限公司，收购价格为人民币646万元，收购日为2022年6月。

| Company name | Disposed through | Net assets as at date of disposal | Net profit from beginning of Reporting Period to date of disposal | Date of disposal |
|------------------|------------------|-----------------------------------|---|------------------|
| ② D 上海医药集团股份有限公司 | 出售 | | | 2022年6月 |

| Company name | Disposed through | Net assets as at date of disposal | Net profit from beginning of Reporting Period to date of disposal | Date of disposal |
|----------------|------------------|-----------------------------------|---|------------------|
| H 上海医药集团股份有限公司 | E 出售 | 30 | | 2022年6月3日 |
| F 上海医药集团股份有限公司 | D 出售 | | | 2022年6月21日 |
| 上海医药集团股份有限公司 | E 出售 | 58 | 5 | 2022年6月28日 |

D. Employees and Remuneration Policies

A ବ , G ବ ବ 36,604 ମ . ମ ' ମ ବ
G ବ ମ ବ , ମ , ବ ବ ବ
ମ .

E. Assets and Liabilities Analysis

A ବ , G ' ବ , ବ ବ ବ - ବ ବ
ବ , ବ 30.85%, ବ ମ 27.13% ବ 31 D ମ 2021.

A ବ , G ' ବ ବମ MB169 ମ , ବ ମ
MB1,115 ମ ବ 31 D ମ 2021. - - ବ ବ ମ
ବ ବ ବ ବ ବ BN G ବ
ବ ମ 2021.

4. Outlook for Operations in the Second Half of 2022

I ବ 2022, G ମ ବ
ବ ବ ବ ବ . G ବ ମ ବ
&D , ମ ବ ବ ବ , ବ
ମ ବ ବ ବ ମ ବ ମ , ବ ମ ବ
ମ ବ ମ ମ ବ ବ , ବ ବ ବ ମ
ବ ବ ବ ମ ବ ମ ବ ବ ବ . I ବ , G
ମ ବ ବ ବ ବ ବ ମ . A ବ ମ , G
ବ ବ ମ ବ ବ ବ ବ ମ ବ , ବ ମ
ବ ବ ବ ମ . I ବ , G ବ ବ
ବ C ID-19 ବ ବ ମ ବ ମ ମ ବ
ବ ବ .

I ବ ବ ବ , G ମ ବ
ବ ବ ବ ବ . S ବ ବ :

Pharmaceutical Manufacturing

I ବ 2022, G ମ ମ 4IN ବ , ବ ବ ବ &D,
ବ ବ ବ ବ ମ
ମ ବ ବ ବ ବ , G ବ ବ
ବ .

Management

D A

Management Discussion and Analysis

The Company's management has conducted a comprehensive review of the company's performance and financial position for the reporting period. The following information provides a detailed overview of the company's operations, financial results, and strategic initiatives.

The Company's revenue for the reporting period was primarily derived from the sale of pharmaceutical products. The revenue was significantly impacted by the global economic environment and the ongoing COVID-19 pandemic, which led to a decrease in demand for certain products and a delay in the launch of new products.

Despite these challenges, the Company has maintained its focus on research and development (R&D) and has successfully launched several new products. The Company's R&D pipeline is robust, and the Company expects to continue to invest in R&D to drive long-term growth.

The Company's financial performance for the reporting period was as follows:

| Item | 2022 | 2021 |
|------------------|-------------|-------------|
| Revenue | XXX million | XXX million |
| Net Profit | XXX million | XXX million |
| Operating Profit | XXX million | XXX million |

The Company's financial position is strong, with a solid balance sheet and a healthy cash flow. The Company's debt-to-equity ratio is low, and the Company has a strong credit rating. The Company's financial performance is expected to improve in the coming years as the Company continues to invest in R&D and expand its product portfolio.

Medical Devices and Medical Diagnosis

The Company's Medical Devices and Medical Diagnosis segment is a key part of its business. The segment's revenue is primarily derived from the sale of medical devices and diagnostic equipment. The segment's performance for the reporting period was as follows:

| Item | 2022 | 2021 |
|------------------|-------------|-------------|
| Revenue | XXX million | XXX million |
| Net Profit | XXX million | XXX million |
| Operating Profit | XXX million | XXX million |

The segment's revenue was impacted by the global economic environment and the ongoing COVID-19 pandemic, which led to a decrease in demand for certain medical devices and diagnostic equipment. Despite these challenges, the segment has maintained its focus on research and development and has successfully launched several new products.

The segment's financial performance is strong, with a solid balance sheet and a healthy cash flow. The segment's debt-to-equity ratio is low, and the segment has a strong credit rating. The segment's financial performance is expected to improve in the coming years as the segment continues to invest in R&D and expand its product portfolio.

I 2022, G

, ,

G

-

G &D

&D

G

&D

A&E

G &D

B &D

G

G

G

,

.

,

Healthcare Services

I 2022, G

,

G

,

,

Management

D A

... G
... HIS
... G
... F
... EHS
... A
... G

... G
... F
... G
... D

... G
... MD
... A
... G

B ... G

B. Market risks

本公司在市場上經營，面臨多種市場風險，包括利率風險、外匯風險、信用風險及價格波動風險。本公司已建立完善的風險管理體系，通過使用金融工具及加強與客戶的合作，有效控制了市場風險。

利率風險：本公司持有大量現金及有價證券，面臨利率變化的風險。本公司通過調整資產負債結構，利用利率衍生品工具，有效管理利率風險。

外匯風險：本公司業務涉及多個國家，面臨外匯匯率波動的風險。本公司通過自然对冲及金融工具，有效管理外匯風險。

信用風險：本公司在經營過程中，面臨客戶及供應商的信用風險。本公司通過嚴格的信用評估及合同管理，有效控制了信用風險。

價格波動風險：本公司產品價格受市場供求關係影響，面臨價格波動的風險。本公司通過加強市場研究及靈活調整定價策略，有效管理價格波動風險。

C. Business and operating risks

(1) R&D risk of drugs

本公司在研發新藥過程中，面臨研發風險，包括技術研發失敗、臨床試驗失敗及監管審批風險。本公司通過加強研發投入、優化研發流程及加強與監管部門的溝通，有效控制了研發風險。

技術研發風險：新藥研發具有高度不確定性，面臨技術研發失敗的風險。本公司通過加強基礎研究及與學術機構的合作，有效管理技術研發風險。

臨床試驗風險：新藥在臨床試驗過程中，面臨試驗失敗的風險。本公司通過嚴格的試驗設計及質量控制，有效管理臨床試驗風險。

監管審批風險：新藥上市需經監管部門審批，面臨審批不通過的風險。本公司通過加強與監管部門的溝通及完善申報資料，有效管理監管審批風險。

B. Inter-bank Market Debt Financing Instruments

I M 2022, C M A M A M 2022. A A A A MB0.5 A A A A 3.50% A A M 2+2 A .

I A 2022, C M A M A A A - M M A A A A 2022. A A A A MB0.6 A A A A 2.65% A A M 120 A .

C. The Public Issuance of Corporate Bonds to Qualified Investors

I F A 2022, A A 2022 ' M A A A (2) A A F A M A A (G) C ., L .* 2018 (18 F A M A 03) (上海復星醫藥(集團)股份有限公司2018年公開發行公司債券(第二期)(品種二)(18復藥03), A A A A C M A M A M A MB8.95 M A A A A M 30 N M 2021 15 F A 2022 (A)).

I M 2022, A M M A MB1,091.95 M A A A A A I A C A B (F A) A A F A M A A (G) C ., L .* A I 2017 (17 F A M A 01) (上海復星醫藥(集團)股份有限公司2017年公開發行公司債券(面向合格投資者)(第一期)(17復藥01) A M A A A .

Statutory D

RESULTS AND DIVIDENDS

For the period ending 30 June 2022, the Group has reported a profit of RMB 64.98 million. The Board of Directors has proposed a dividend of RMB 0.04 per share for the period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

No listed securities were purchased, sold or redeemed during the period.

DIRECTORS

As at 30 June 2022, the Board consists of nine members:

Executive Directors

- M. Y. F. (吳以芳) (Chairman)
- M. K. (王可心) (Co-Chairman)
- M. G. (關曉暉) (Vice-Chairman)

Non-executive Directors

- M. C. (陳啟宇)
- M. F. (姚方)
- M. (徐曉亮)
- M. D. (潘東輝)

Independent Non-executive Directors

- M. L. L. (李玲)
- M. G. (湯谷良)
- M. (王全弟)
- M. S. H. (余梓山)

The Board of Directors met on 1 July 2022. The Board has approved the financial statements for the period ending 30 June 2022, and has proposed a dividend of RMB 0.04 per share for the period. The Board also approved the appointment of Mr. Y. F. as Chairman, Mr. K. as Co-Chairman, and Mr. G. as Vice-Chairman. The Board also approved the appointment of Mr. C., Mr. F., Mr. X., and Mr. D. as Non-executive Directors, and the appointment of Ms. L., Mr. G., Mr. W., and Mr. S. as Independent Non-executive Directors.

Statutory D

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

As at 25 J 2019, the Company has granted 1,704,440 share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 12 months. The share options are subject to the terms and conditions of the Scheme.

As at 17 Mv 2020, the Company has granted 154,950 share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 12 months. The share options are subject to the terms and conditions of the Scheme.

As at 27 J 2019, the Company has granted 103 share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 12 months. The share options are subject to the terms and conditions of the Scheme.

As at 17 Mv 2020, the Company has granted (1) share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 12 months. The share options are subject to the terms and conditions of the Scheme.

| Participant | Date of Grant (dd-mm-yyyy) | Vesting Period (dd-mm-yyyy) ⁽¹⁾ | Option share ⁽¹⁾ | Exercise period (dd-mm-yyyy) ⁽¹⁾ | Outstanding options as at 1 January 2022 | Exercise price per share | Granted | Exercised | Forfeited or | Outstanding options as at 30 June 2022 |
|---------------|-------------------------------|---|--------------------------------|--|--|--------------------------------|--------------------------------------|--|--|--|
| | | | | | | | during the Reporting Period | during the Reporting Period ⁽²⁾ | lapsed during the Reporting Period | |
| Emp v v | 27 6 2019 | 27 6 2019 - 19 11 2020 | 40% | 20 11 2020 - 26 6 2029 | 455,500 | IN 542 | 0 | 353,200 | 0 | 102,300 |
| | | 27 6 2019 - 30 3 2021 | 30% | 31 3 2021 - 26 6 2029 | | | | | | |
| | | 27 6 2019 - 30 3 2022 | 30% | 31 3 2022 - 26 6 2029 | | | | | | |

Notes:

(1) The exercise price of the share options is IN 542 per share.

(2) The exercise price of the share options is IN 3,219.12 per share.

Fosun Health Share Option Scheme

1J 2022. F H a S a S m v v v v v v v
 v F H a G ' , v v m v m v v v
 G ' - m m . F H a

v v v v v v v v v m v v v
 F H a S a S m v MB380,435,000 v v F H a , v
 10% v v v F H a v v v F H a S a S m v
 v v v v ' m F H a . v v v v F
 H a S a S m MB1.0 v . F v () v v v v ,
 v 50% v v v (. . . MB1 v v) F H a (v) v
 m v v v v v F H a v v v v v (. .
 MB1 v v) F H a v m v , v v v v v
 v v v v v . F H a S a S m v v v v
 10 v m v v F H a S a S m v v v ' m
 F H a .

D , F H a v F H a S a S m .

Statutory

D

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2022, the interests and short positions of the directors, supervisors and chief executive of the Company in the shares, underlying shares and debentures of the Company and any other entities, and the interests and short positions of the directors, supervisors and chief executive of the Company in the shares, underlying shares and debentures of any other entities, are as follows:

(1) Long positions in the Shares, underlying Shares and debentures of the Company

| Name of Directors/ chief executive | Capacity | Class of Shares | Number of Shares ⁽¹⁾ | Approximate percentage of Shares in relevant class |
|---------------------------------------|----------|-----------------|---------------------------------|---|
|---------------------------------------|----------|-----------------|---------------------------------|---|

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2022, the following persons, companies or entities (collectively, "substantial shareholders") were known to the Company to have a substantial interest in the issued shares of the Company, being shares which carry or are entitled to exercise 5% or more of the total voting rights in the Company at the time of the meeting of the shareholders.

| Name of Shareholders | Nature of interest | Class of Shares | Number of Shares ⁽¹⁾ | Approximate percentage of Shares in relevant class of Shares |
|----------------------|--------------------|-----------------|---------------------------------|--|
| F. H. | Beneficial | Ordinary | 71,533,500 (L) | 12.96% |
| | Beneficial | Preference | 938,095,290 (L) | 46.65% |
| F. I. A. A. | Beneficial | Ordinary | 6,000,000 (L) | 1.09% |
| | Beneficial | Ordinary | 71,533,500 (L) ⁽²⁾ | 12.96% |
| | Beneficial | Preference | 938,095,290 (L) ⁽⁴⁾ | 46.65% |
| F. H. | Beneficial | Ordinary | 77,533,500 (L) ⁽³⁾ | 14.05% |
| | Beneficial | Preference | 938,095,290 (L) ⁽⁴⁾ | 46.65% |
| F. I. A. A. H. | Beneficial | Ordinary | 77,533,500 (L) ⁽³⁾ | 14.05% |
| | Beneficial | Preference | 938,095,290 (L) ⁽⁴⁾ | 46.65% |
| M. G. G. A. A. | Beneficial | Ordinary | 77,533,500 (L) ⁽³⁾ | 14.05% |
| | Beneficial | Preference | 938,095,290 (L) ⁽⁴⁾ | 46.65% |
| B. A., I. . | Beneficial | Preference | 114,075 (L) | 0.01% |
| | Beneficial | Ordinary | 29,489,216 (L) | 5.34% |
| | | | 401,000 (S) | 0.07% |

Notes:

(1) (L) Long term; (S) Short term.

(2) The shares were held by F. H. as beneficial owner. F. I. A. A. is the registered holder.

(3) The shares were held by F. H. as beneficial owner. F. I. A. A. is the registered holder. F. H. holds 72.45% of the shares. F. I. A. A. holds 72.45% of the shares. F. H. is the beneficial owner of 72.45% of the shares.

(4) The shares were held by F. H. as beneficial owner. F. I. A. A. is the registered holder. F. H. holds 85.29% of the shares. M. G. G. A. A. is the beneficial owner of 85.29% of the shares.

Statutory D

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Section 70 of the Companies Act, 2013, provides that a company may, by its articles of association, restrict or regulate the rights of its directors and supervisors to acquire shares or debentures of the company. The company may also provide that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Model Code for Securities Transactions sets out the guidelines for the directors and supervisors of a company. It provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange. The code also provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange.

COMPLIANCE WITH THE CG CODE

The Companies (Directors and Officers) Securities Trading Regulations, 2015 (CG Code) sets out the guidelines for the directors and supervisors of a company. It provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange. The code also provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange.

The CG Code also provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange. The code also provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange.

Section 2.1 of the CG Code provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange. The code also provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange.

Section 1J of the CG Code provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange. The code also provides that the directors and supervisors shall not be entitled to acquire shares or debentures of the company if the company is a public company or a company listed on a stock exchange.

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

A 董 事 會 謹 啟
D 敬 啟 者 本 公 司 之 中 期 業 績 及 中 期 報 告 業 經 審 計 委 員 會 審 閱 。

審 計 委 員 會 認 為 本 公 司 之 中 期 業 績 及 中 期 報 告 之 內 容 與 本 公 司 之 中 期 業 績 及 中 期 報 告 之 內 容 一 致 。

本 公 司 之 中 期 業 績 及 中 期 報 告 之 內 容 業 經 審 計 委 員 會 審 閱 。

Wu Yifang
Chairman

2022年6月29日

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

L

For the six months ended 30 June 2022

| | | For the six months ended | |
|---|-------|--------------------------|-------------|
| | | 30 June | |
| | | 2022 | 2021 |
| | | RMB'000 | MB'000 |
| | Notes | (Unaudited) | () |
| | | | () |
| REVENUE | 5 | 21,274,606 | 16,877,537 |
| C | | (11,575,661) | (8,256,422) |
| G | | 9,698,945 | 8,621,115 |
| S | 6 | 183,645 | 141,714 |
| A | | (4,166,397) | (4,211,431) |
| A | | (1,715,275) | (1,505,057) |
| I | | (1,818,335) | (1,561,885) |
| I | | (22,860) | (14,804) |
| F | 7 | 651,104 | 1,645,255 |
| S | | (911,494) | (338,367) |
| J | | 118,416 | 116,605 |
| A | 8 | (438,187) | (420,725) |
| J | | (99,564) | (93,817) |
| A | | 898,583 | 925,626 |
| PROFIT BEFORE TAX | 9 | 2,378,581 | 3,304,229 |
| I | 10 | (509,086) | (550,647) |
| PROFIT FOR THE PERIOD | | 1,869,495 | 2,753,582 |
| A | | 1,553,504 | 2,482,373 |
| N | | 315,991 | 271,209 |
| | | 1,869,495 | 2,753,582 |
| EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT | 12 | | |
| B | | RMB0.60 Yuan | MB0.97 |
| F | | | |
| D | | RMB0.60 Yuan | MB0.97 |
| F | | | |

Interim Condensed Consolidated

Sam C m I m

For the six months ended 30 June 2022

| | For the six months ended 30 June | |
|--|-------------------------------------|-----------------------|
| | 2022 RMB'000 (Unaudited) | 2021 MB'000 () |
| PROFIT FOR THE PERIOD | 1,869,495 | 2,753,582 |
| OTHER COMPREHENSIVE INCOME | | |
| E a : S a m () a m a a S a m ()/ m a a | 115,920 | (201,712) |
| | 48 | (804) |
| | (71,933) | 54,912 |
| Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods | 44,035 | (147,604) |
| E : C a a a I m a | (8,121) | 5,200 |
| | 1,218 | (780) |
| | (6,903) | 4,420 |
| S a m m a a | — | 10,725 |
| Net other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods | (6,903) | 15,145 |
| OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX | 37,132 | (132,459) |
| TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | 1,906,627 | 2,621,123 |
| A a : | 1,622,372 | 2,385,072 |
| N - | 284,255 | 236,051 |
| | 1,906,627 | 2,621,123 |

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

30 June 2022

| | Notes | 30 June 2022 RMB'000 (Unaudited) | 31 December 2021 MB'000 (Audited) |
|---|-------|---|--|
| NON-CURRENT ASSETS | | | |
| Property, plant and equipment | 13 | 13,890,670 | 13,011,818 |
| Intangible assets | | 2,634,025 | 2,569,796 |
| Goodwill | | 9,933,642 | 9,399,987 |
| Investments in associates | | 12,555,179 | 11,610,712 |
| Investments in subsidiaries | | 299,227 | 282,837 |
| Equity instruments in subsidiaries | | 22,835,121 | 22,343,990 |
| Financial assets at fair value through profit or loss | | 21,795 | 29,916 |
| Derivatives | | 1,634,964 | 1,206,489 |
| Other non-current assets | | 320,388 | 265,589 |
| | | 77,469 | 77,395 |
| | | 2,414,451 | 2,013,740 |
| | | 66,616,931 | 62,812,269 |
| CURRENT ASSETS | | | |
| Accounts receivable | 14 | 6,143,790 | 5,472,315 |
| Prepayments | | 7,292,310 | 6,045,460 |
| Financial assets at fair value through profit or loss | | 3,038,152 | 3,466,043 |
| Derivatives | | 2,386,620 | 4,241,069 |
| Other current assets | | 554,168 | 427,884 |
| Current tax receivable | | 12,258,061 | 10,308,157 |
| | | 31,673,101 | 29,960,928 |
| Accounts payable | | 463,705 | 463,705 |
| | | 32,136,806 | 30,424,633 |
| CURRENT LIABILITIES | | | |
| Accounts payable | 15 | 5,707,081 | 5,063,661 |
| Other current liabilities | | 6,621,586 | 7,020,048 |
| Income tax payable | 16 | 17,569,068 | 15,460,243 |
| Loans | | 170,838 | 141,496 |
| Contract liabilities | | 1,207,096 | 1,150,274 |
| Other current liabilities | | 691,691 | 474,223 |
| | | 31,967,360 | 29,309,945 |
| NET CURRENT ASSETS | | 169,446 | 1,114,688 |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | 66,786,377 | 63,926,957 |

Interim Condensed Consolidated

Sam Fara

30 June 2022

| | Notes | 30 June 2022 RMB'000 (Unaudited) | 31 Dec 2021 MB'000 (A) |
|--|-------|---|----------------------------------|
| NON-CURRENT LIABILITIES | | | |
| Long-term debt | 16 | 12,033,558 | 9,049,069 |
| Lease liabilities | | 687,975 | 648,360 |
| Deferred tax liabilities | | 3,273,451 | 3,129,746 |
| Contract liabilities | | 176,007 | 239,011 |
| Other non-current liabilities | | 520,014 | 512,806 |
| | | 2,412,002 | 2,029,287 |
| | | 19,103,007 | 15,608,279 |
| Net assets | | 47,683,370 | 48,318,678 |
| EQUITY | | | |
| Equity attributable to owners of the parent | | | |
| Share capital | | 2,562,899 | 2,562,899 |
| Reserves | | 35,585,198 | 36,572,163 |
| | | 38,148,097 | 39,135,062 |
| Non-controlling interests | | 9,535,273 | 9,183,616 |
| Total equity | | 47,683,370 | 48,318,678 |

Interim Condensed Consolidated

Statement of Financial Position

For the period ended 30 June 2022

Attributable to owners of the parent

| | Share capital | Share premium | Fair value reserve | Statutory surplus reserve | Other reserve | Exchange fluctuation reserve | Retained profits | Total | Non-controlling interests | Total equity |
|---------------------------------------|---------------|---------------|--------------------|---------------------------|---------------|------------------------------|------------------|-------------|---------------------------|--------------|
| | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 | RMB'000 |
| As at 30 June 2022 (As reported) | 2,562,899 | 11,385,162* | 203,703* | 2,826,306* | 2,784,724* | (1,457,965)* | 20,830,233* | 39,135,062 | 9,183,616 | 48,318,678 |
| As at 30 June 2021 (As reported) | — | — | — | — | — | — | 1,553,504 | 1,553,504 | 315,991 | 1,869,495 |
| Share-based payment expense | — | — | (6,471) | — | — | — | — | (6,471) | (432) | (6,903) |
| Share-based payment expense | — | — | (71,885) | — | — | — | — | (71,885) | — | (71,885) |
| Exchange rate fluctuations | — | — | — | — | — | 147,224 | — | 147,224 | (31,304) | 115,920 |
| Share repurchase | — | — | (78,356) | — | — | 147,224 | 1,553,504 | 1,622,372 | 284,255 | 1,906,627 |
| Share-based payment expense | — | — | — | — | (1,150,544) | — | — | (1,150,544) | (74,382) | (1,224,926) |
| Share-based payment expense (note 17) | — | — | — | — | — | — | — | — | 196,369 | 196,369 |
| Share-based payment expense | — | — | — | — | — | — | — | — | 1,360 | 1,360 |
| Share-based payment expense | — | — | — | — | 4,922 | — | — | 4,922 | 11,421 | 16,343 |
| Share-based payment expense | — | — | — | — | (9,435) | — | — | (9,435) | — | (9,435) |
| Share-based payment expense | — | — | — | — | — | — | — | — | 23,151 | 23,151 |
| Share-based payment expense | — | — | — | — | — | — | — | — | (141,048) | (141,048) |
| Share-based payment expense | — | — | — | — | — | — | — | — | (15,420) | (15,420) |
| Share-based payment expense | — | — | — | — | — | — | — | — | 61,756 | 61,756 |
| Share-based payment expense | — | — | — | — | (28,381) | — | — | (28,381) | 2,020 | (26,361) |
| Share-based payment expense | — | — | — | — | 9,566 | — | — | 9,566 | 2,175 | 11,741 |
| Share-based payment expense (note 11) | — | — | — | — | — | — | (1,435,465) | (1,435,465) | — | (1,435,465) |
| Share-based payment expense | — | — | (33,142) | — | — | — | 33,142 | — | — | — |
| As at 30 June 2022 (As reported) | 2,562,899 | 11,385,162* | 92,205* | 2,826,306* | 1,610,852* | (1,310,741)* | 20,981,414* | 38,148,097 | 9,535,273 | 47,683,370 |

* As at 30 June 2021, the fair value reserve was RMB35,585,198,000 (31 December 2021: RMB36,572,163,000).

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

For the six months ended 30 June 2022

| | | For the six months ended | |
|---|----|--------------------------|-------------|
| | | 30 June | |
| | | 2022 | 2021 |
| | | RMB'000 | MB'000 |
| | | (Unaudited) | () |
| | | Notes | |
| Cash and cash equivalents | | 2,221,854 | 2,094,337 |
| Less: Cash equivalents | | (401,483) | (387,696) |
| Net cash and cash equivalents | | 1,820,371 | 1,706,641 |
| CASH FLOWS FROM INVESTING ACTIVITIES | | | |
| Acquisition of intangible assets | | (2,595,334) | (2,286,070) |
| Acquisition of subsidiaries | 17 | (459,451) | (21,391) |
| Disposal of subsidiaries | | (239,719) | (100,172) |
| Disposal of equity investments | | (252,071) | (191,752) |
| Disposal of property, plant and equipment | | 6,581 | 537,242 |
| Disposal of financial assets | | 1,256,217 | 80,764 |
| Disposal of other investments | 18 | 704,493 | 237,609 |
| Disposal of other assets | | 55,719 | 61,154 |
| Disposal of other liabilities | | 32,175 | 8,009 |
| Disposal of other intangible assets | | 103,686 | 18,421 |
| Disposal of other financial assets | | (25,000) | (12,392) |
| Disposal of other non-current assets | | (1,310,390) | (819,125) |
| Disposal of other non-current liabilities | | 161,366 | 6,509 |
| Disposal of other non-current assets | | 76,573 | 31,450 |
| Net cash used in investing activities | | (2,485,155) | (2,449,744) |

Interim Condensed Consolidated

Sum Ca F

For the six months ended 30 June 2022

| | For the six months ended 30 June | |
|---|-------------------------------------|-----------------------|
| | 2022 RMB'000 (Unaudited) | 2021 MB'000 () |
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| N | 17,847,543 | 14,234,577 |
| | (12,918,555) | (12,719,442) |
| I | (448,224) | (419,549) |
| | (88,200) | (68,914) |
| Ca | 41,508 | 251,362 |
| D | (1,335,223) | |
| D | (74,686) | (69,024) |
| A | (1,088,182) | (530,770) |
| B | 411,520 | |
| | 72,683 | 91,429 |
| N | 2,420,184 | 769,669 |
| N | 1,755,400 | 26,566 |
| Ca | 6,450,650 | 7,324,881 |
| E | 68,077 | (103,270) |
| Ca | 8,274,127 | 7,248,177 |
| Analysis of balances of cash and cash equivalents: | | |
| Ca | 12,258,061 | 10,489,133 |
| L | (3,983,934) | (3,240,956) |
| Ca | 8,274,127 | 7,248,177 |

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

- (a) Application of HKF 33 *Framework for the Preparation and Presentation of Financial Statements* and HKF 37 *Conceptual Framework for Financial Reporting* (2018)
- HKF 33 and HKF 37 were issued in 2018. The Group has adopted these standards from 1 July 2022. The adoption of HKF 33 and HKF 37 does not have any impact on the Group's financial statements.
- (b) Application of HKAS 16 *Property, Plant and Equipment* (2013)
- HKAS 16 was amended in 2013. The Group has adopted this amendment from 1 July 2021. The adoption of HKAS 16 does not have any impact on the Group's financial statements.
- (c) Application of HKAS 37 *Provisions, Contingent Liabilities and Contingent Assets* (2003)
- HKAS 37 was amended in 2003. The Group has adopted this amendment from 1 July 2022. The adoption of HKAS 37 does not have any impact on the Group's financial statements.
- (d) Application of HKF 1, HKF 9, IAS 1 and EAS 1
- HKF 1, HKF 9, IAS 1 and EAS 1 were issued in 2018-2020. The Group has adopted these standards from 1 July 2022. The adoption of HKF 1, HKF 9, IAS 1 and EAS 1 does not have any impact on the Group's financial statements.
- HKF 9 *Financial Instruments*: The Group has adopted HKF 9 from 1 July 2022. The adoption of HKF 9 does not have any impact on the Group's financial statements.

Notes to Interim Condensed Consolidated

F a a l m a

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2022 (unaudited)

| | Pharmaceutical manufacturing RMB'000 | Medical devices and medical diagnosis RMB'000 | Healthcare Service RMB'000 | Pharmaceutical distribution and retail RMB'000 | Other business operations RMB'000 | Eliminations RMB'000 | Total RMB'000 |
|-----------------------------------|--|--|----------------------------------|---|---|-------------------------|------------------|
| Segment revenue: | | | | | | | |
| Σ a a m | 14,270,930 | 4,034,954 | 2,916,662 | — | 52,060 | — | 21,274,606 |
| l m a | 140,363 | 214,035 | 43,313 | — | 9,334 | (407,045) | — |
| a | 14,411,293 | 4,248,989 | 2,959,975 | — | 61,394 | (407,045) | 21,274,606 |
| Segment results* | | | | | | | |
| m | 1,889,837 | 439,669 | (386,703) | — | 41,388 | (20,930) | 1,963,261 |
| a | 103,862 | 11,334 | 15,396 | — | 11,013 | — | 141,605 |
| l m | 302,498 | 301,515 | 47,933 | — | — | — | 651,946 |
| F a | 83,261 | 7,596 | 12,901 | — | 110 | (5,711) | 98,157 |
| | (105,897) | (14,518) | (89,415) | — | (4,325) | 49,853 | (164,302) |
| | (229,699) | (28,089) | (19,820) | — | 14,642 | 305 | (262,661) |
| Σ a a : | | | | | | | |
| J | (96,979) | — | — | — | (2,585) | — | (99,564) |
| A a | 14,208 | 93,494 | (16,446) | 919,864 | (112,537) | — | 898,583 |
| a a m, m, | | | | | | | |
| a, a, a | | | | | | | (848,444) |
| /() a | 1,961,091 | 811,001 | (436,154) | 919,864 | (52,294) | 23,517 | 2,378,581 |
| a | (382,366) | (111,764) | (5,670) | — | (23) | — | (499,823) |
| a a a | | | | | | | (9,263) |
| /() | 1,578,725 | 699,237 | (441,824) | 919,864 | (52,317) | 23,517 | 1,869,495 |
| Segment assets: | 51,748,370 | 10,007,104 | 11,108,724 | 16,774,252 | 5,021,141 | (2,539,162) | 92,120,429 |
| l : | | | | | | | |
| Investments in joint ventures | 290,610 | — | 832 | — | 7,785 | — | 299,227 |
| Investments in associates | 1,318,013 | 1,250,089 | 893,241 | 16,774,252 | 2,599,526 | — | 22,835,121 |
| a a a | | | | | | | 6,633,308 |
| a a | | | | | | | 98,753,737 |
| Segment liabilities: | 22,453,057 | 3,539,092 | 5,408,677 | — | 1,497,902 | (15,682,906) | 17,215,822 |
| a a a | | | | | | | 33,854,545 |
| a a | | | | | | | 51,070,367 |
| Other segment information: | | | | | | | |
| D a a a m a | 722,087 | 115,279 | 206,588 | — | 20,372 | — | 1,064,326 |
| l m a m a m | | | | | | | |
| | 65,473 | 20,319 | 11,628 | — | — | — | 97,420 |
| C a a ** | 1,800,755 | 155,846 | 196,281 | — | 21,210 | — | 2,174,092 |

* Σ m a a a m a, a, a m a a a a

** C a a a m, a a a a a a a m

Note: a m a a m a m a a B N a a m

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

| | Revenue | Cost of sales | Operating expenses | Other income | Other expenses | Segment revenue | Segment results* |
|---------------------------------------|------------|---------------|--------------------|--------------|----------------|-----------------|------------------|
| | MB'000 | MB'000 | MB'000 | MB'000 | MB'000 | MB'000 | MB'000 |
| Segment revenue: | | | | | | | |
| Pharmaceuticals | 12,179,257 | 2,832,211 | 1,843,434 | 22,635 | | 16,877,537 | |
| Life Sciences | 13,233 | 17,779 | 20,501 | 12,639 | (64,152) | | |
| | 12,192,490 | 2,849,990 | 1,863,935 | 35,274 | (64,152) | 16,877,537 | |
| Segment results* | 1,352,891 | 434,099 | (19,393) | 9,266 | (23,352) | 1,753,511 | |
| Pharmaceuticals | 102,012 | 14,123 | 15,428 | 7,430 | | 138,993 | |
| Life Sciences | 201,990 | 2,283 | 87,416 | 262,270 | (111,725) | 442,234 | |
| Investments | 85,180 | 16,516 | 14,508 | 1,698 | (14,636) | 103,266 | |
| Finance | (80,436) | (13,698) | (25,545) | (5,312) | 21,894 | (103,097) | |
| | (35,582) | (34,764) | (12,181) | (258,830) | | (341,357) | |
| Share of profit of associates: | | | | | | | |
| Share of profit of associates | (93,805) | | | | (12) | | (93,817) |
| Share of profit of associates | 35,707 | 90,143 | (28,178) | 896,991 | (69,037) | | 925,626 |
| Share of profit of associates | | | | | | | 478,870 |
| /() | 1,567,957 | 508,702 | 32,055 | 896,991 | (52,527) | (127,819) | 3,304,229 |
| | (311,399) | (54,486) | (47,288) | | (2) | | (413,175) |
| | | | | | | | (137,472) |
| /() | 1,256,558 | 454,216 | (15,233) | 896,991 | (52,529) | (127,819) | 2,753,582 |
| Segment assets: | 46,659,269 | 8,322,272 | 9,898,810 | 15,355,639 | 4,458,138 | (2,668,056) | 82,026,072 |
| Investments in joint ventures | 342,929 | | | | 6,148 | | 349,077 |
| Investments in associates | 2,273,758 | 555,078 | 1,589,874 | 15,355,639 | 2,673,511 | | 22,447,860 |
| | | | | | | | 6,396,412 |
| | | | | | | | 88,422,484 |
| Segment liabilities: | 17,422,127 | 2,202,799 | 2,555,456 | | 710,137 | (10,426,621) | 12,463,898 |
| | | | | | | | 28,918,999 |
| | | | | | | | 41,382,897 |
| Other segment information: | | | | | | | |
| Depreciation and amortization | 643,074 | 123,971 | 157,392 | | 21,010 | | 945,447 |
| Impairment losses | (1,288) | 25,438 | 7,872 | | 190,114 | | 222,136 |
| Carrying amount of non-current assets | 1,323,129 | 137,508 | 477,910 | | 102,565 | | 2,041,112 |

* Segment results are calculated based on the accounting policies of the respective operating segments. The accounting policies of the operating segments are consistent with the accounting policies of the Group.

** Carrying amount of non-current assets is calculated based on the carrying amount of non-current assets less accumulated depreciation and impairment losses.

Note: All amounts are in million RMB unless otherwise specified.

Notes to Interim Condensed Consolidated

F a a I m a

30 June 2022

5. REVENUE

A a a a :

| | | | | For the six months ended | |
|---|---|---|---|--------------------------|------------|
| | | | | 30 June | |
| | | | | 2022 | 2021 |
| | | | | RMB'000 | MB'000 |
| | | | | (Unaudited) | (a) |
| | m | a | m | 21,258,760 | 16,864,028 |
| G | a | m | | 15,846 | 13,509 |
| | | | | 21,274,606 | 16,877,537 |

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2022 (unaudited)

| Segments | Pharmaceutical manufacturing RMB'000 | Medical devices and medical diagnosis RMB'000 | Healthcare service RMB'000 | Other business operations RMB'000 | Total RMB'000 |
|--------------------------------------|--|---|----------------------------------|---|------------------|
| Types of goods or services | | | | | |
| Sa | 13,844,207 | 3,915,452 | 441,291 | — | 18,200,950 |
| | 418,473 | 89,828 | 2,472,638 | 41,175 | 3,022,114 |
| Sa m a | 6,625 | 29,071 | — | — | 35,696 |
| | 14,269,305 | 4,034,351 | 2,913,929 | 41,175 | 21,258,760 |
| Geographical markets | | | | | |
| Ma a C a | 9,253,783 | 1,460,631 | 2,913,290 | 39,753 | 13,667,457 |
| | 5,015,522 | 2,573,720 | 639 | 1,422 | 7,591,303 |
| | 14,269,305 | 4,034,351 | 2,913,929 | 41,175 | 21,258,760 |
| Timing of revenue recognition | | | | | |
| G a a a m | 13,850,832 | 3,944,523 | 441,291 | — | 18,236,646 |
| S a a a m | 276,437 | 33,096 | 2,472,638 | 41,175 | 2,823,346 |
| S a m | 142,036 | 56,732 | — | — | 198,768 |
| | 14,269,305 | 4,034,351 | 2,913,929 | 41,175 | 21,258,760 |

Notes to Interim Condensed Consolidated

F a a | M a

30 J 2022

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2021 (unaudited)

| S M | M a | | H a a | | | |
|--------------------------------------|------------|-----------|-----------|--------|--------|------------|
| | M a a a | M a a | M a a | M a a | M a a | M a a |
| | MB'000 | MB'000 | MB'000 | MB'000 | MB'000 | MB'000 |
| Types of goods or services | | | | | | |
| S a | 11,733,205 | 2,742,001 | 37,479 | | | 14,512,685 |
| | 414,422 | 76,259 | 1,804,041 | 11,459 | | 2,306,181 |
| S a M a a | 30,599 | 13,951 | 612 | | | 45,162 |
| a M a a M | 12,178,226 | 2,832,211 | 1,842,132 | 11,459 | | 16,864,028 |
| Geographical markets | | | | | | |
| M a a C a | 8,474,661 | 1,339,179 | 1,842,132 | 10,040 | | 11,666,012 |
| a a | 3,703,565 | 1,493,032 | | 1,419 | | 5,198,016 |
| a M a a M | 12,178,226 | 2,832,211 | 1,842,132 | 11,459 | | 16,864,028 |
| Timing of revenue recognition | | | | | | |
| G a a a M | 11,763,804 | 2,755,952 | 38,091 | | | 14,557,847 |
| S a a a M | 297,157 | 13,239 | 1,804,041 | 11,459 | | 2,125,896 |
| S a M | 117,265 | 63,020 | | | | 180,285 |
| a M a a M | 12,178,226 | 2,832,211 | 1,842,132 | 11,459 | | 16,864,028 |

Notes to Interim Condensed Consolidated

F a n a l 2022

30 June 2022

10. INCOME TAX

For the six months ended 30 June 2022, the Group's income tax expense is primarily attributable to the income tax payable on the Group's taxable income in the PRC. The Group's income tax expense is calculated based on the Group's taxable income in the PRC and the applicable income tax rates. The Group's income tax expense is calculated based on the Group's taxable income in the PRC and the applicable income tax rates. The Group's income tax expense is calculated based on the Group's taxable income in the PRC and the applicable income tax rates.

The Group's income tax expense is calculated based on the Group's taxable income in the PRC and the applicable income tax rates. The Group's income tax expense is calculated based on the Group's taxable income in the PRC and the applicable income tax rates. The Group's income tax expense is calculated based on the Group's taxable income in the PRC and the applicable income tax rates.

| | For the six months ended | |
|--------------|--------------------------|----------------|
| | 2022 | 2021 |
| | RMB'000 | MB'000 |
| | (Unaudited) | (Audited) |
| C | 603,241 | 451,937 |
| D | (94,155) | 98,710 |
| Total | 509,086 | 550,647 |

11. DIVIDENDS

On 30 June 2022, the Board of Directors of the Company has proposed a final dividend of RMB0.56 per share for the year ended 31 December 2021. The dividend is subject to the approval of the shareholders at the annual general meeting of the Company to be held in 2022.

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

| | | For the six months ended 30 June | |
|-----------------|--|-------------------------------------|-----------------------|
| | | 2022 RMB'000 (unaudited) | 2021 MB'000 () |
| Earnings | | | |
| | | 1,553,504 | 2,482,373 |
| | | 1,553,504 | 2,482,373 |
| Shares | | | |
| | | 2,562,898,545 | 2,562,898,545 |
| | | 2,562,898,545 | 2,562,898,545 |
| G | | 30 J 2022. | |

Notes to Interim Condensed Consolidated

F a a l 2022

30 June 2022

13. PROPERTY, PLANT AND EQUIPMENT

| | | For the six months ended 30 June | |
|----|------|-------------------------------------|-------------|
| | | 2022 | 2021 |
| | | RMB'000 | MB'000 |
| | | (Unaudited) | () |
| Cn | 1 Jn | 13,011,818 | 12,579,873 |
| A | | 1,552,693 | 1,481,681 |
| A | | 44,342 | 790 |
| D | | (21,878) | (46,840) |
| D | | (78,349) | (1,434,727) |
| D | | (609,401) | (564,429) |
| E | | (8,555) | (29,439) |
| Cn | 30 J | 13,890,670 | 11,986,909 |

G ' , n n m n n n MB771,550,000 (31 D m 2021:
MB550,040,000), n - n n n n 16 m

Notes to Interim Condensed Consolidated

F a a | m a

30 June 2022

15. TRADE AND BILLS PAYABLES (Continued)

| | | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|---------------------------|--|---|--------------------------------|
| A a a a a a a a a a a a : | | | |
| <hr/> | | | |
| a a a : | | | |
| 1 a | | 4,758,515 | 4,466,889 |
| 2 a | | 79,408 | 26,002 |
| 2 3 a | | 13,503 | 14,949 |
| 3 a | | 10,721 | 7,433 |
| <hr/> | | 4,862,147 | 4,515,273 |
| <hr/> | | | |

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

| | | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|-------------|-------|---|--------------------------------|
| | | 25,917,685 | 19,623,059 |
| Ba a : | Notes | | |
| a | (1) | 1,494,670 | 1,402,634 |
| <hr/> | | 24,423,015 | 18,220,425 |
| <hr/> | | | |
| a - m m a a | (2) | 600,000 | 1,200,000 |
| C a | (3) | 3,084,941 | 3,686,253 |
| <hr/> | | 29,602,626 | 24,509,312 |
| <hr/> | | | |
| a a a | | (17,569,068) | (15,460,243) |
| <hr/> | | | |
| N - | | 12,033,558 | 9,049,069 |
| <hr/> | | | |

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

| A a a a - a a a a : | 30 June 2022 RMB'000 (Unaudited) | 31 D m 2021 MB'000 (A) |
|---------------------|---|----------------------------------|
| a a : | | |
| 1 a | 17,569,068 | 15,460,243 |
| 2 a | 4,444,947 | 4,875,505 |
| 2 5 a | 5,451,125 | 1,787,641 |
| 5 a | 2,137,486 | 2,385,923 |
| | 29,602,626 | 24,509,312 |
| a a a | (17,569,068) | (15,460,243) |
| N - | 12,033,558 | 9,049,069 |

Notes:

(1) Bank loans

| a a a a a a m 0.3000% 4.8300% (31 D m 2021: 0.3000% 6.0000%) a m. |
|--|
| A a 30 J 2022, a G ' a a a a m a a a G ' , a a m (13) a m MB 771,550,000 (31 D m 2021: MB550,040,000), a a a a m - - a a m MB511,229,000 (a a a a m - - a 31 D m 2021: MB513,993,000). |
| A a 30 J 2022, a G ' a a a a G ' a a a a (14) a m MB99,940,000 (31 D m 2021: MB69,444,000) a a a m MB8,417,000 (31 D m 2021: MB8,296,000). |
| A a 30 J 2022, G a m a a a m m a (31 D m 2021: MB7,742,000). |
| A a 30 J 2022, G 58.67% a s B a M a C , L . a a a (31 D m 2021: 58.67% s B a). |

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

Notes: (Continued)

(2) Super Short-term Commercial Paper

| | | | | | | | | | | |
|------|-------|-------|---|-------|-----|-----|-------|----------------|-------|---------|
| 13 A | 2022, | C m a | - | m m m | a a | a a | a a m | MB600,000,000, | a | a 2.65% |
| a m. | | | - | m m m | a a | a a | m a | 11 A | 2022. | |

(3) Corporate bonds

| | | | | | | | | | | |
|----------------|---------|-------|----------------|----------------|------------------|-------|-------|------------------|----------|---|
| 13 A | 2018, | C m a | a | a m a | a a a | a a a | a a m | MB1,300,000,000, | a | |
| a 3.50% | a m. | | a a a a | a a a | m a | a | 13 A | 2023. A a 30 J | 2022, | a |
| - a | a | | MB746,651,000. | | | | | | | |
| 30 N | m 2018, | C m a | a | a m a | a a a | a a a | a a m | MB500,000,000, | a | |
| a 3.83% | a m. | | a a a a | a a a | m a | a | 30 N | m 2022. A a 30 J | 2022, | a |
| a | - a | a | MB239,848,000. | | | | | | | |
| 2 F | a 2021, | C m a | a | a m a | a a a | a a a | a a m | MB1,600,000,000, | a | |
| a 3.98% | a m. | | a a a a | a a a | m a | a | 2 F | a 2025. S | a | |
| a m a | a , a | | , a | , C m a | a | a | a | a | a a | |
| a m a | a | | - a | a (a m 2023), | a | a | a | a | a a 30 J | |
| 2022. A a 30 J | 2022, | a | - a | a | MB1,599,242,000. | | | | | |
| 9 M a | 2022, | C m a | m m m | a m a | a a a | a a a | a a m | MB500,000,000, | a | |
| a 3.50% | a m. | | a a a a | a a a | m a | a | 9 M a | 2026. A a 30 J | 2022, | a |
| - a | a | | MB499,200,000. | | | | | | | |

17. BUSINESS COMBINATION

20 J a a 2022, S a a F H a (G) C ., L ., a a C m a , a 70%
 G a a C ., L . * (廣州新市醫院有限公司) (H a) m a a .
 a a a MB 809,200,000. A a , G 70%
 H a .

* E a m m a C m a a a m a C m a a a
 C a m m a .

Notes to Interim Condensed Consolidated

F a r | 2022

30 J 2022

17. BUSINESS COMBINATION (Continued)

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000

17. BUSINESS COMBINATION(Continued)

An analysis of the cash flows in respect of the acquisitions of subsidiaries is as follows:

Notes to Interim Condensed Consolidated

F n n | m n

30 J 2022

18. DISPOSAL OF SUBSIDIARIES

D m 30 J 2022, G n n m n n n
 H n A M n n C .,L . A n n n n n C .,L , 51%
 J n H n n n n C .,L .* (江蘇黃河藥業股份有限公司), n n
 MB125,328,000. n n 3 J n n 2022. n n n n n
 n m G n .

D m 30 J 2022, G n n m n n n G n
 (n) C .,L ., 100% n n n B n n C .,L .*
 (上海輸血技術有限公司), n n MB390,000,000. n n 28 F n 2022.
 n n n n n n G n .

*

Notes to Interim Condensed Consolidated

F a a l m a

30 June 2022

18. DISPOSAL OF SUBSIDIARIES (Continued)

| A a a | | a a a a | | a a a | | : | MB'000 |
|-------|---|---------|-----|-------|---|---|----------|
| C a | a | | | | | | 421,905 |
| C a | | a | a | | | | 319,220 |
| C a | a | a | a a | | | | (36,632) |
| N | | a a a | a | | a | a | 704,493 |

19. COMMITMENTS

| G a | | a a m m m a | | : | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|-------|---------------|-------------|--|---|---|--------------------------------|
| C a , | : | | | | 2,415,887 | 2,127,421 |
| I m | a a m | | | | 2,487,233 | 2,066,497 |
| I m | F a a a a a a | | | | 513,177 | 451,933 |
| A | : | | | | 2,544,064 | 3,128,531 |
| | | | | | 7,960,361 | 7,774,382 |

Notes to Interim Condensed Consolidated

F a n a l m a

30 J 2022

20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

| | For the six months ended | |
|--|--------------------------|------------------|
| | 2022 | 2021 |
| | RMB'000 | MB'000 |
| | (Unaudited) | (a) |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 6 & 15) | 2,210,042 | 1,809,891 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 16) | 365,650 | 326,501 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8) | 11,744 | 40 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | 4,670 | 5,139 |
| Fosun Pharmaceutical (Group) Co., Ltd. (notes 2 & 4) | 3,222 | 2,030 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | 2,930 | 7,936 |
| Fosun Pharmaceutical (Group) Co., Ltd. (notes 3 & 4 & 10 & 16) | 2,749 | 252 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | 2,335 | 2,436 |
| Jiangsu Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | 537 | 1,251 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | 447 | 6 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 6) | 179 | 2,039 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 2 & 4) | 123 | 671 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8) | 57 | |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 7) | 19 | 19 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | 10 | 26 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8 & 17) | 5 | 6 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 18) | — | 637 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8 & 19) | — | 148 |
| Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8) | — | 4 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4) | — | 3 |
| | 2,604,719 | 2,159,035 |

Notes to Interim Condensed Consolidated

F a r a | ୩୩

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

| | For the six months ended | |
|---|--------------------------|----------------|
| | 2022 | 2021 |
| | RMB'000 | MB'000 |
| | (Unaudited) | () |
| ଝି ବାମ୍ପିଂ ଚିକିତ୍ସା କର୍ମସଂସ୍ଥା (notes 4 & 6 & 15) | 168,498 | 178,674 |
| ଫିଲିପ୍ସ ଲାଭକାରୀ କର୍ମସଂସ୍ଥା (notes 3 & 4 & 11 & 16) | 72,128 | 22,575 |
| ଚିକିତ୍ସା ସଂସ୍ଥା ସିଏଚ୍ ସିଏଲ୍ ଏସ୍ (notes 1 & 4 & 16) | 19,470 | 18,434 |
| ଫିଲିପ୍ସ ହାଲିକା କର୍ମସଂସ୍ଥା (notes 4 & 8) | 12,854 | 627 |
| ଫିଲିପ୍ସ (ଇଣ୍ଡିଆ) ମାଧ୍ୟମିକ କର୍ମସଂସ୍ଥା (notes 4 & 6) | 8,892 | — |
| ଫିଲିପ୍ସ ଇଣ୍ଡିଆ ମାଧ୍ୟମିକ (ଇଣ୍ଡିଆ) କର୍ମସଂସ୍ଥା (notes 4 & 7) | 5,407 | — |
| ଝି ବାମ୍ପିଂ ବାଲି (notes 1 & 4) | 3,204 | 12,041 |
| ଏସ୍ ଝି ବାମ୍ପିଂ ବାଲି କର୍ମସଂସ୍ଥା (notes 1 & 4) | 632 | 1,034 |
| ଝିଏନ୍ଏମ୍ ବାଲି & କର୍ମସଂସ୍ଥା (notes 1 & 4) | 179 | 1,306 |
| ଝିଏଲ୍ ବାଲି କର୍ମସଂସ୍ଥା (notes 1 & 4) | 3 | 55 |
| ଗବର୍ଣ୍ଣମେଣ୍ଟ କର୍ମସଂସ୍ଥା (notes 4 & 8 & 19) | — | 34,544 |
| ହାଲିକା ବାଲି କର୍ମସଂସ୍ଥା (notes 1 & 4) | — | 105 |
| | 291,267 | 269,395 |

(c) Leasing and property management services

| | | |
|--|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee

For the six months ended 30 June 2022

| Types of leased assets | | Rental charges for short-term/low-value assets leases | Additions of right-of-use assets |
|------------------------|-------------------------|---|----------------------------------|
| F | I a a L m a a | | |
| | (notes 3 & 5 & 13 & 16) | 9,454 | 23,569 |

For the six months ended 30 June 2021

| | | | |
|-----------|-------------------------|-------|-----|
| | | a a | |
| | | - m/ | A |
| | | - a | - - |
| | a a | a a | a |
| F | I a a L m a a | | |
| | (notes 3 & 5 & 13 & 16) | 5,242 | |
| D a a a a | LL (notes 5 & 8 & 19) | 114 | |
| sh a a | LL (notes 5 & 8 & 19) | 41 | |
| | | 5,397 | |

For the six months ended
30 June

| | 2022 RMB'000 (Unaudited) | 2021 MB'000 () |
|-------------------------------------|---------------------------------------|-----------------------|
| Property management services | | |
| F | I a a L m a a (notes 3 & 5 & 14 & 16) | |
| | 11,732 | 6,818 |

Notes to Interim Condensed Consolidated

F a a | m

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to a related parties

| | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|---|---|--------------------------------|
| Deposits in Fosun Finance | | |
| F F a (notes 3 & 16) | 870,551 | 974,576 |
| Loans from Fosun Finance | | |
| F F a (notes 3 & 16) | 111,686 | 116,127 |
| Loans to Fosun Kite Biological Technology Co., Ltd | | |
| <p> 2018 12 2019 16 2022.D A 30 J 2022, MB 113,000(31 D 2021: MB 188,840,000), MB 138,445,000(31 D 2021: MB 301,000). </p> | | |
| F K B a C ., L (note 2) | 138,558 | 189,141 |

Notes to Interim Condensed Consolidated

F a r E a s t

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans to Nature's Sunshine (Far East) Limited

Na ture's Sunshine (Far East) Limited (Far East) Limited (note 1)
 2022. D 2021. G
 MB1,927,000
 3%
 MB1,927,000.

| | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|--|---|--------------------------------|
| Na ture's Sunshine (Far East) Limited (note 1) | — | 1,927 |

Loans to StarKids Children's Hospital Shanghai

StarKids Children's Hospital Shanghai (note 1)
 2022. A 30 J 2021: MB94,000).
 MB9,291,000
 MB273,000(31 D 2021: MB94,000).

| | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|--|---|--------------------------------|
| StarKids Children's Hospital Shanghai (note 1) | 9,564 | 9,385 |

Loans to Shanghai Xingmai Information Technology Co., Ltd.

Shanghai Xingmai Information Technology Co., Ltd. (note 1)
 2022. D 2021: 29
 MB71,400,000
 10%
 (31 D 2021: MB1,864,000).

| | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|--|---|--------------------------------|
| Shanghai Xingmai Information Technology Co., Ltd. (note 1) | — | 73,264 |

Notes to Interim Condensed Consolidated

F a a | m

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans from Shanghai Youle Information Technology Co., Ltd.

ଶା ଯୁଲେ ଇଫ ଟି ଏସ୍ ଲିମିଟେଡ୍ (ଶା ଯୁଲେ ଇଫ ଟି ଏସ୍ ଲିମିଟେଡ୍) C ., L . ରୁ ଋଣାଣା MB5,492,000 ଫି ହି ଭା (ଶା ଯୁଲେ ଇଫ ଟି ଏସ୍ ଲିମିଟେଡ୍) C ., L . ରୁ ଋଣାଣା 4.35% ରୁ ୧୯ ୨୦୨୧ ୧୮ ୨୦୨୨. A ଋ ୩୦ J ୨୦୨୨, ଋ ଋ ଋ MB160,000 (31 D ୧୯ ୨୦୨୧: MB40,000).

| | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|-------------------------------------|---|--------------------------------|
| ଶା ଯୁଲେ ଇଫ ଟି ଏସ୍ ଲିମିଟେଡ୍ (note 3) | 5,652 | 5,532 |

Loans from Shanghai Fosun High Tech (Group) Company limited

ଶା ଫୋସୁନ ହାଇ ଟେକ୍ (ଗ୍ରୁପ୍) କମ୍ପାନୀ ଲିମିଟେଡ୍ (ଶା ଫୋସୁନ ହାଇ ଟେକ୍ (ଗ୍ରୁପ୍) କମ୍ପାନୀ ଲିମିଟେଡ୍) C ଲିମିଟେଡ୍ ରୁ ଋଣାଣା MB18,673,000 ଫି ହି ଭା (ଶା ଫୋସୁନ ହାଇ ଟେକ୍ (ଗ୍ରୁପ୍) କମ୍ପାନୀ ଲିମିଟେଡ୍) C ., L . ରୁ ଋଣାଣା 4.35% ରୁ ୧୯ ୨୦୨୧ ୧୮ ୨୦୨୨. A ଋ ୩୦ J ୨୦୨୨, ଋ ଋ ଋ MB543,000 (31 D ୧୯ ୨୦୨୧: MB137,000).

| | 30 June 2022 RMB'000 (Unaudited) | 31 D 2021 MB'000 (A) |
|--|---|--------------------------------|
| ଶା ଫୋସୁନ ହାଇ ଟେକ୍ (ଗ୍ରୁପ୍) କମ୍ପାନୀ ଲିମିଟେଡ୍ (note 3) | 19,216 | 18,810 |

(e) Interest income from/interest expense to related parties

| | Six months ended 30 June | |
|---|--------------------------------|------------------------|
| | 2022 RMB'000 (Unaudited) | 2021 MB'000 (A) |
| Interest income | | |
| ଫି କି ଏସ୍ ଲିମିଟେଡ୍ C ., L . (note 2) | 4,248 | 4,678 |
| ଫି ଫି ଏସ୍ (notes 3 & 16) | 4,026 | 4,560 |
| ଶା କି ଏସ୍ ' H ଋ ଶା ଋ (note 1) | 180 | 182 |
| ନି ଏସ୍ ' ଶା (ଫି ଏସ୍) L ଲିମିଟେଡ୍ (note 1) | 14 | 112 |
| | 8,468 | 9,532 |

Notes to Interim Condensed Consolidated

F a n a l r e p o r t

30 J u n e 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (Continued)

| | 2022 | 2021 |
|--------------------------------------|--|--|
| Interest income from related parties | 0.35% (F o r 30 J u n e 2022) | 0.35% (F o r 30 J u n e 2021) |
| Interest expense to related parties | 1.485%-1.89% (F o r 30 J u n e 2022) | 1.89% (F o r 30 J u n e 2021) |
| Interest income from related parties | 1.15% (F o r 30 J u n e 2022) | 1.15% (F o r 30 J u n e 2021) |
| Interest expense to related parties | 1.55% - 1.755% (F o r 30 J u n e 2022) | 1.55% - 1.755% (F o r 30 J u n e 2021) |

| Interest expense | Six months ended 30 June | |
|---|--------------------------------|-------------------------------------|
| | 2022 RMB'000 (Unaudited) | 2021 MB'000 (a u d i t e d) |
| F i n a n c i n g (n o t e s 3 & 16) | 2,666 | 1,432 |
| U t i l i t i e s (G a s) C o n s u m p t i o n (n o t e s 3 & 16) | 406 | |
| U t i l i t i e s I n t e r n e t C o n n e c t i o n L a n d l e d (n o t e s 3 & 16) | 119 | |
| | 3,191 | 1,432 |

Notes:

- (1) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (2) Interest expense to related parties is primarily from the borrowing of funds from related parties.
- (3) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (4) Interest expense to related parties is primarily from the borrowing of funds from related parties.
- (5) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (6) Interest expense to related parties is primarily from the borrowing of funds from related parties.
- (7) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (8) Interest expense to related parties is primarily from the borrowing of funds from related parties.
- (9) In A u g u s t 2021, C o n s u m p t i o n C o n t r a c t H o l d i n g s , F o r e i g n C o n s u m p t i o n C o n t r a c t H o l d i n g s

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (Continued)

Notes: (Continued)

(11) During the reporting period, the Group has entered into various financial transactions with related parties. The Group has provided loans to related parties, including the subsidiary companies, and has received interest income from these parties. The Group has also entered into various financial transactions with related parties, including the subsidiary companies, and has received interest income from these parties. The Group has also entered into various financial transactions with related parties, including the subsidiary companies, and has received interest income from these parties.

Notes to Interim Condensed Consolidated

F a a | m

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(g) Donations

| | Six months ended 30 June | |
|-------------|--------------------------------|-----------------------|
| | 2022 RMB'000 (Unaudited) | 2021 MB'000 () |
| Δ a a F F a | 7,502 | 8,708 |

F m 30 J 2022, G a MB7,502,000 (m 30 J 2021: MB8,708,000) a a Δ a a F F a .

(h) Outstanding balances with related parties:

- () A a 30 J 2022, G a a a a m m a m a a MB1,705,659,000 (31 D m 2021: MB1,725,786,000). a a , - a a m , F F a .
- () A a 30 J 2022, G a a a a m a a m a a MB1,016,575,000 (31 D m 2021: MB994,289,000). a a , - a a a m , a Na ' Δ (Fa Ea) L m a Δ a K C ' H a Δ a a .
- () A a 30 J 2022, a a m a a MB143,923,000 (31 D m 2021: MB194,222,000) , - a a m , a F K .
- () A a 30 J 2022, a a m a m MB11,869,000 (31 D m 2021: MB10,856,000) , - a a a a m .
- () A a 30 J 2022, G a a a a m a m a a MB216,497,000 (31 D m 2021: MB197,757,000). a a , - a a a m , m Δ a a I m a C , L , F F a a Δ a a F H (G) C m a L m .
- () A a 30 J 2022, a a a a m a a MB312,662,000 (31 D m 2021: MB317,922,000) a a , - a a a m a m .
- () A a 30 J 2022, a a a a m MB6,696,000 (31 D m 2021: MB6,696,000) a - a a , , - a a a m a m .

Notes to Interim Condensed Consolidated

F a a | m a

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

a a a a m a m a G ' a a m :

Assets measured at fair value:

As at 30 June 2022 (Unaudited)

| | Quoted prices in active markets (Level 1) RMB'000 | Fair value measurement using Significant observable inputs (Level 2) RMB'000 | Significant unobservable inputs (Level 3) RMB'000 | Total RMB'000 |
|---------------|---|---|---|------------------|
| F a a a a a a | 1,924,337 | 389,335 | 1,707,912 | 4,021,584 |
| E m a a a a | 4,073 | 17,722 | — | 21,795 |
| D m a a a | — | 554,168 | — | 554,168 |
| | 1,928,410 | 961,225 | 1,707,912 | 4,597,547 |

As at 31 December 2021 (Audited)

| | Fa a m a m a a a a | (L 1) MB'000 | (L 2) MB'000 | (L 3) MB'000 | a MB'000 |
|---------------|-----------------------|-----------------|-----------------|-----------------|-------------|
| F a a a a a a | | 3,259,068 | 573,994 | 1,614,496 | 5,447,558 |
| E m a a a a | | 5,380 | 24,536 | — | 29,916 |
| D m a a a | | — | 427,884 | — | 427,884 |
| | | 3,264,448 | 1,026,414 | 1,614,496 | 5,905,358 |

Notes to Interim Condensed Consolidated

Fair Value

30 J 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

Table with columns for categories and amounts.

For the six months ended 30 June 2022

| | Financial assets at fair value through profit and loss RMB'000 (Unaudited) | Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited) |
|----------------|--|--|
| At 1 Jan 2022 | 1,614,496 | — |
| Change | (31,879) | — |
| Acquisition | 121,970 | — |
| Disposal | 42,586 | — |
| At 30 Jun 2022 | 1,707,912 | — |

For the six months ended 30 June 2021

| | Fair Value | |
|--|---------------|--|
| | 44 million | |
| | 002 million | |
| | 114 million | |
| | 71'000 | |
| | (159,575,210) | |
| | 114 million | |
| | 002 million | |
| | 114 million | |
| | 71'000 | |
| | (159,575,210) | |

Notes to Interim Condensed Consolidated

F a a I m a

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

As at 30 June 2022 (Unaudited)

| | | Fair value measurement using | | | Total RMB'000 |
|----|-----|---|---|---|------------------|
| | | Quoted prices in active Markets (Level 1) RMB'000 | Significant observable inputs (Level 2) RMB'000 | Significant unobservable inputs (Level 3) RMB'000 | |
| Am | m a | — | — | 2,152,663 | 2,152,663 |

As at 31 December 2021 (Audited)

| | | Fair value measurement using | | | Total MB'000 |
|----|-----|--|--|--|-----------------|
| | | Quoted prices in active Markets (Level 1) MB'000 | Significant observable inputs (Level 2) MB'000 | Significant unobservable inputs (Level 3) MB'000 | |
| Am | m a | | | 1,729,070 | 1,729,070 |

m m a a m a m L 3 a a :

| | | | | | |
|--|--|--|--|--|--|
| | | | | | |
| | | | | | |

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

22. CONTINGENT LIABILITIES

A a 30 J 2022 a 31 D m 2021, G a a a .

23. EVENTS AFTER THE REPORTING PERIOD

Non-public offering of A shares

I J 2022, C m a 106,756,666 A- a 10 a - a a
 MB42.00 a , a a a m a a MB4,483,779,972.00. a a
 A- a m a a a a B a C a a D a C a
 C a L m 27 J 2022. A- a a a a a a - . a
 a a a a a 6 m m a m a a a .

24. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

m a a a a m a a a a D
 29 A 2022.

Definitions

| | | |
|------------|------------|------------------|
| C.S.C | C.S.C | 中國證券監督管理委員會 |
| D () | D () | 中國 |
| D | D | 董事 |
| E | E | 董事 |
| E 有限公司 | E 有限公司 | 上海復星醫藥有限公司 |
| FIC | FIC | 財政部 |
| F 有限公司 | F 有限公司 | 佛山復星禪誠醫院有限公司 |
| H 有限公司 | H 有限公司 | 佛山市禪城區中心醫院有限公司 |
| F D 有限公司 | F D 有限公司 | 復星診斷科技(上海)有限公司 |
| F H 有限公司 | F H 有限公司 | 上海復星健康科技(集團)有限公司 |
| F H G 有限公司 | F H G 有限公司 | 上海復星醫療(集團)有限公司 |
| F H 有限公司 | F H 有限公司 | 上海復星醫藥(集團)有限公司 |

| | |
|----------------------|--|
| F K | F K B 復星凱特生物科技有限公司), 有限公司 |
| F 復星醫藥有限公司 | 上海復星醫藥產業發展有限公司), 有限公司 |
| G B | H 河南真實生物科技有限公司) |
| G 復星 | G 復星() Limited 復星醫藥有限公司 F-LLC |
| G 復星 | G 復星 Limited, 復星醫藥有限公司, 復星醫藥有限公司, BSE 及 NSE (證券代號: G) |
| G 復星 2019 年 5 月 25 日 | 2019 年 5 月 25 日 |
| GM | G M 復星醫藥有限公司 |
| G | C 復星醫藥有限公司 (復星醫藥有限公司) |
| G 復星醫藥 | 國藥控股國大藥房有限公司) |
| G 復星醫藥 | G 復星醫藥有限公司), 有限公司 |
| H 2019 年 5 月 25 日 | 2019 年 5 月 25 日 |
| H K 復星醫藥 | H K 復星醫藥 |
| H K L | G L 復星醫藥有限公司 |
| H K 復星醫藥 | 復星醫藥有限公司 |
| H 復星醫藥 | J 復星醫藥有限公司), 有限公司 |
| H K | H K 復星醫藥有限公司 |
| IN | , 復星醫藥有限公司 |

Definitions

| | | |
|-----------|--|---------------------|
| I F HK | I 蘇 復 星 (H K) C ., L ., 有 限 公 司 | H K 復 星 醫 藥 有 限 公 司 |
| I F 蘇 復 星 | I 蘇 復 星 M 復 星 (蘇 復 星) C ., L . * (直 觀 復 星 醫 療 器 械 技 術 (上 海)有 限 公 司), 有 限 公 司 | C 蘇 復 星 |
| I F | I F HK 復 星 I F 蘇 復 星 | |
| K 復 星 | K E C ., 有 限 公 司 | N 復 星 |
| M 復 星 | M 復 星 蘇 復 星 A 復 星 | C |
| M | M E C K S H A & D H M E C ., 有 限 公 司 | 蘇 復 星 |
| M C | | |

Definitions

| | |
|---|---------------------------------------|
| H | 新市醫院有限公司 (廣州新市醫院有限公司) (A 新市醫院有限公司) |
| G | 廣東藥科大學附屬第三醫院 (廣東藥科大學附屬第三醫院), 新市醫院有限公司 |
| F | 徐州風友匯藥品零售有限公司 (徐州風友匯藥品零售有限公司), F 2022 |
| B | 亞能生物技術(深圳)有限公司 (亞能生物技術(深圳)有限公司) |
| C | 重慶藥友製藥有限責任公司 (重慶藥友製藥有限責任公司), C |
| I | 重慶藥友製藥有限責任公司 (重慶藥友製藥有限責任公司), C |
| * | F |